Compositions and methods

JP7579245B2Active Publication Date: 2024-11-07OXFORD UNIVERSITY INNOVATION LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021523773
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-06
Filing Date
2019-11-05
Publication Date
2024-11-07
Estimated Expiration
2039-11-05

AI Technical Summary

Benefits of technology

【0123】 抗原発現 抗原はウイルスベクターから恒常的に発現していてもよい。実際、本発明者らは、本明細書に記載する、抗原を恒常的に発現するウイルスベクターが多数の継代を通じて安定であることを示している。これは本発明の利点である。しかしながら、所望により、抗原の発現は、製造の間抑制してもよく、これにより、より良い収率がもたらされ得る、及び/又は抗原毒性による問題を回避し得る。これは操作者の選択の問題である。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579245000005
    Figure 0007579245000005
  • Figure 0007579245000006
    Figure 0007579245000006
  • Figure 0007579245000007
    Figure 0007579245000007
Patent Text Reader

Abstract

The present invention relates to a viral vector comprising a nucleic acid having a polynucleotide sequence encoding at least one epitope of the Varicella-Zoster Virus (VZV) GlyE antigen, said viral vector being an adenoviral vector. The present invention also relates to uses in medical treatment, compositions for use, and methods of medical treatment.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions useful for inducing an immune response against Varicella-Zoster Virus (VZV), in particular to viral vectors, such as adenoviral vectors, that contain an epitope derived from the VZV GlyE protein. [Background technology]

[0002] The varicella zoster virus (VZV or "varicella zoster virus") causes chickenpox primarily in children, but more importantly, it can re-emerge in adults, usually decades after primary chickenpox infection, and cause the severe disease shingles.

[0003] Shingles, also known as herpes zoster, is an infection of the nerves and surrounding skin. According to the UK's National Health Service, it is estimated that around one in four people will have at least one episode of shingles in their lifetime.

[0004] The main symptoms of shingles are pain and then a rash that progresses to itchy blisters similar in appearance to those in chickenpox. New blisters may appear for up to a week, but after a few days they become yellowish in color, flatten, and dry. Crusts then form from where the blisters were, which may leave some slight scarring and loss of skin pigment. The pain may be constant, dull, or burning, and its intensity may vary from mild to severe. Patients may have a sharp stinging pain at times, and the affected areas of the skin are usually sensitive. In some cases, shingles may cause some early symptoms that occur several days before the painful rash first appears, such as headaches, burning, tingling, numbness, or itching of the skin in the affected areas, a general feeling of being unwell, and / or a high fever (fever).

[0005] An episode of shingles typically lasts about 2-4 weeks. It usually affects a specific area on only one side of the body. It does not usually span the midline of the body. It can affect any part of the body, such as the face and eyes, but the chest and abdomen are the most common areas.

[0006] With life expectancy in the UK now exceeding 80 years, maintaining long-term health is a key objective of modern healthcare. Medical advances that specifically target more frequent and impactful diseases in older adults, such as shingles, can play an important role in reducing the burden of disease and associated healthcare demand.

[0007] Over 90% of adults have been infected with the Varicella Zoster Virus (VZV) and are therefore at risk of developing shingles (herpes zoster). Shingles is most frequent in older adults (over age 50), but can occur at any age, especially in people who are immunocompromised (have a weakened immune system). Normally, the immune system is able to control the virus, but later in life, VZV can reactivate and result in shingles. It is not clear why this may occur, but it may be related to immunosenescence (the gradual deterioration of the immune system brought on by aging). The development of a vaccine that specifically protects against the disease targeting older adults is an important health care step.

[0008] It is desirable to reduce the severity of symptoms and / or the risk of developing complications. Complications of shingles include meningitis or encephalitis, and if shingles affects the eye, there is a risk of developing permanent vision problems if the condition is not promptly treated.

[0009] European Patent No. 3210631 discloses a DNA vaccine composition for preventing and treating herpes zoster and a method for activating T cells for VZV antigens using the same. This document describes a DNA vaccine composition for preventing and treating herpes zoster, which contains at least one type of plasmid containing an insertion site for a gene derived from varicella zoster virus (VZV) encoding a VZV protein and other pharma- ceutical acceptable components. There is no mention of a viral vector in this document.

[0010] WO 2014 / 043189 discloses conditionally replication-deficient herpes viruses and their use in vaccines. It describes the creation of variant or mutated herpes viruses and host cells that contain one or more destabilizing domains that are made conditionally replication-deficient by incorporating or fusing one or more genes essential for viral replication. There is no mention of viral vectors in this document.

[0011] EP 1721981 discloses recombinant varicella zoster virus prepared using BAC (E. coli artificial chromosome) and pharmaceutical compositions containing such virus. The focus of this document is on the identification of non-essential regions of VZV, in particular the non-essential regions are the regions adjacent to the ORF of gene 11 or the regions adjacent to the ORF of gene 12. There is no mention in this document of a viral vector carrying a VZV antigen.

[0012] WO 2009 / 012486 discloses varicella zoster virus virus-like particles (VLPs) and antigens. In particular, this document describes purified virus-like particles (VLPs) derived from Varicella Zoster Virus (VZV) that contain VZV gE protein but do not contain VZV nucleic acid or yeast Ty protein. The focus of this document is on VLPs that further contain at least one additional protein from an infectious agent. The only mention of viral vectors in this document is in paragraphs 0048-0049 as generic expression vectors.

[0013] Prior art vaccines against this virus include Zostavax™ (Merck). Protection with Zostavax™ is primarily mediated by an antibody response. European Medicines Agency (EMA) document WC500053460 discusses Zostavax and claims that in the art a correlation between immune response and protection against Herpes Zoster (HZ) has been observed by gpELISA measurement, whereas results of VZV IFN-γ ELISPOT testing had a less clear correlation to protection. Zostavax™ is typically administered to all adults aged 70 years in the UK. However, the vaccine is not completely effective and its usefulness against shingles decreases with age (from 69.8% in adults aged 50-59 years to 37.6% in adults aged 70 years or older). Thus, efficacy is 30-40%, which is very poor. This is a problem in the art. Furthermore, the protection afforded by Zostavax™ typically lasts no longer than five years, which is troublingly short.

[0014] Furthermore, the vaccine is not recommended for people with weakened immune systems (e.g., patients with HIV) who are at high risk of developing shingles. Thus, there is an unmet need for a vaccine that provides improved protection across all ages, but especially in elderly and immunocompromised populations.

[0015] Zostavax™ is a live attenuated virus. Therefore, when administered to humans, it causes limited infection and enhances the immune response in humans without causing shingles disease. It should be noted that this formulation does not replicate in mice, and therefore, when administered to mice, it is more similar to administering a replication-deficient virus.

[0016] SHINGRIX™ is a vaccine indicated for the prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX™ is manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium. SHINGRIX™ is prepared by reconstituting lyophilized Varicella Zoster Virus glycoprotein E (gE) antigen components with the accompanying AS01B adjuvant suspension components. Thus, SHINGRIX™ is a protein vaccine based on the GlyE antigen. To be effective, it must be administered as two doses. Each dose must be administered with an adjuvant, such as AS01 adjuvant. This adjuvant is reactogenic, which can be unpleasant for patients - 85% of recipients report pain upon injection. Possible side effects of SHINGRIX™ include redness, itching, swelling, warmth, bruising or pain at the injection site. Headache, muscle pain, fatigue or fever may also occur. Furthermore, reactogenicity may cause secondary problems of compliance, since the response experienced after vaccine administration discourages patients from returning for a second dose, which is necessary to complete the recommended regimen and associated level of protection. This is a problem in the art.

[0017] A further drawback of prior art approaches, such as the SHINGRIX™ vaccine, is that they require two vials of material to be stored and mixed at the time of administration - in the case of SHINGRIX™, this is a vial of adjuvant and a vial of antigen, which are formulated into a single mixture at the time of administration.

[0018] In the United States, the list price for Zostavax is $196.91 per dose in the private sector and $117.12 per dose for the CDC vaccine contract. With regard to reimbursement, Zostavax is covered by most private health insurers (98%) for adults age 60 and older in the United States (although some plans may require copayments). The vaccine is also covered by Medicare for adults age 65 and older, although there will often be copayments and out-of-pocket expenses. Additionally, critics have identified Shingrix's two-dose administration and its tolerability profile as potentially weak. Thus, there are persistent problems with the prior art approach.

[0019] The present invention seeks to overcome the problems associated with the prior art. [Prior art documents] [Patent documents]

[0020] [Patent Document 1] European Patent No. 3210631 [Patent Document 2] International Publication No. 2014 / 043189 Brochure [Patent Document 3] European Patent No. 1721981 [Patent Document 4] International Publication No. 2009 / 012486 Brochure [Non-patent literature]

[0021] [Non-Patent Document 1] European Medicines Agency document WC500053460 Summary of the Invention [Problem to be solved by the invention]

[0022] Lack of adequate cell-mediated immunity (CMI) against the varicella zoster virus (VZV) is associated with a higher risk of developing shingles and associated pain. [Means for solving the problem]

[0023] The present invention describes adenovirus-GlyE varicella zoster virus vaccines, which have been shown to induce T cell responses. These vectors can be used in prime-boost vaccination regimens. The data provided in this application demonstrates strong T cell responses. Thus, the present invention provides advantageous, strong and sustained T cell responses.

[0024] Varicella zoster virus (VZV) causes chickenpox and herpes zoster (shingles). Chickenpox is a highly contagious disease caused by initial infection with Varicella zoster virus (VZV). Chickenpox is one of the most common childhood diseases, characterized by a blister-like rash and fever, with over 90% of the population exposed during the first 20 years of life. Chickenpox is generally a mild, self-limited disease, but can become severe in immunocompromised subjects and adults. Zoster or shingles is caused by reactivation of VZV, which persists in a latent form in the posterior sensory ganglia. Prevention of chickenpox by vaccination is a desirable medical intervention.

[0025] It should be noted that the compositions and / or vaccines described herein are not therapeutic, i.e., they are not taught to remove / eradicate the virus. They are taught as vaccine compositions for use in maintaining control of VZV infection and / or preventing recurrence of replicative VZV infections that cause shingles. In other words, the compositions are taught as vaccine compositions for use in inducing an immune response from the host organism, and not as drugs that act directly against the virus itself. The compositions are useful for inducing protection against early infections such as chickenpox and / or inducing protection against reactivation of latent viruses (sometimes referred to as "dormant viruses") such as shingles.

[0026] Suitably, reference to "existing infection" means "latent infection" or "static infection", i.e. a virus in the lysogenic stage of its life cycle, i.e. a dormant VZV infection (defined as no longer causing active infection).

[0027] Suitably, references to "infection" have their normal meaning in the art, i.e. an active or productive viral infection causing disease such as chickenpox or shingles, most suitably shingles. An "infection" will usually have an associated viremia, i.e. an active infection (rather than a latent infection as discussed above).

[0028] Suitably the compositions described herein are for use in the prevention of recurrent VZV infection, suitably for use in the prevention of replicating VZV infection, suitably for use in the prevention of disease caused by reactivation of latent VZV infection.

[0029] Without wishing to be bound by theory, the inventors believe that the recurrence of the virus that causes shingles in adults may be due to the gradual decline of T cell response / T cell number against circulating virus.For this reason, the inventors teach for the first time that existing approaches (mainly based on antibody response) may not be suitable for this purpose.For these reasons, the inventors teach the claimed viral vector constructs, which have the advantage of protecting recipients by inducing strong cellular immune response, for example T cell response.

[0030] In a broad aspect, the present invention relates to a viral vector comprising a nucleic acid having a polynucleotide sequence encoding at least one epitope of the Varicella Zoster Virus (VZV) GlyE antigen. Suitably the viral vector and the Varicella Zoster Virus (VZV) GlyE antigen are heterologous, i.e. suitably the viral vector is not VZV or is not derived from VZV.

[0031] Suitably, the present invention relates to a viral vector comprising a nucleic acid having a polynucleotide sequence encoding at least one epitope of the Varicella-Zoster Virus (VZV) GlyE antigen, wherein said viral vector is an adenoviral vector.

[0032] In one aspect, the present invention relates to a composition comprising a viral vector comprising a nucleic acid having a polynucleotide sequence encoding at least one epitope of a Varicella-Zoster Virus (VZV) GlyE antigen, wherein said viral vector is an adenoviral vector.

[0033] Suitably, said at least one epitope comprises at least one CD4 T cell epitope and at least one CD8 T cell epitope.

[0034] Suitably, the adenoviral vector is of human or simian origin.

[0035] Suitably, the adenoviral vector is ChAdOx1 or ChAdOx2.

[0036] Suitably the composition is adjuvant-free.

[0037] Suitably, the GlyE antigen has the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, suitably SEQ ID NO:2.

[0038] Suitably, the polynucleotide sequence comprises the sequence of SEQ ID NO:3 or SEQ ID NO:4, suitably SEQ ID NO:4.

[0039] Suitably, the polynucleotide sequence further comprises the sequence of the bgh polyadenylation signal of SEQ ID NO:6.

[0040] Suitably, said polynucleotide sequence encoding at least one epitope of the Varicella Zoster Virus (VZV) GlyE antigen is operably linked to a long CMV promoter, suitably the long CMV promoter has the nucleotide sequence of SEQ ID NO:7.

[0041] Suitably, the viral vector sequence is that of ECACC Accession No. 12052403 (ChAdOx1).

[0042] Suitably, the viral vector sequence is as follows SEQ ID NO:5 (ChAdOx2).

[0043] Suitably, administration of a single dose to a mammalian subject induces protective immunity in said subject.

[0044] Suitably, the composition is formulated such that administration of a single dose of said composition to a mammalian subject induces protective immunity in said subject.

[0045] Suitably, the composition is for inducing an immune response against VZV.

[0046] Suitably, said immune response is a cellular immune response. Suitably, said cellular immune response comprises an NK cell response and / or a T cell response. Suitably, said cellular immune response comprises a T cell response. Suitably, said T cell response comprises a CD8+ T cell response. Suitably, said T cell response comprises a CD4+ T cell response. More suitably, said T cell response comprises a CD8+ and CD4+ T cell response. Most suitably, said T cell response comprises a CD4+ T cell response. Suitably, said T cell response comprises a triple secretory CD4+ T cell response.

[0047] Suitably, the composition is for inducing an immune response against VZV and is administered in a single dose.

[0048] Suitably, the composition is for inducing an immune response against VZV and is administered once.

[0049] The present invention advantageously provides a composition that has the advantage of being effective when administered only once.However, in one embodiment, if the immune response in a subject fades over time, the composition can be suitably administered (re-administered) to said subject.For example, the composition can be administered once every 5 years, more suitably once every year.

[0050] Suitably, the composition is for inducing an immune response against VZV and said composition is administered once every five years, more suitably once a year.

[0051] Suitably, the composition is for preventing VZV infection.

[0052] Suitably, the composition is for preventing shingles.

[0053] Suitably the composition is for preventing VZV infection or for preventing shingles and is administered in a single dose.

[0054] Suitably, the composition is for preventing VZV infection or for preventing shingles, and the composition is administered once.

[0055] Suitably, the composition is for use in the prevention of VZV infection.

[0056] Suitably the composition is for use in the prevention of shingles.

[0057] Suitably the composition is for use in the prevention of VZV infection or for use in the prevention of shingles and is administered in a single dose.

[0058] Suitably the composition is for use in the prevention of VZV infection or for use in the prevention of shingles, and the composition is administered once.

[0059] In one aspect, the present invention relates to the use of the above composition in medicine.

[0060] In one aspect, the present invention relates to the use of the above-mentioned composition in the preparation of a medicament for preventing VZV infection.

[0061] In one aspect, the present invention relates to the use of the above composition in the preparation of a medicament for the prevention of shingles.

[0062] In one aspect, the invention relates to the use of the above composition in the preparation of a medicament for inducing, or for inducing, both a CD4+ and a CD8+ T cell response against the GlyE antigen in a subject, suitably said medicament further inducing antibodies against the GlyE antigen in said subject.

[0063] In one aspect, the present invention relates to a method of inducing an immune response against Varicella Zoster Virus (VZV) in a mammalian subject, comprising administering to said subject a composition as described above.

[0064] In one aspect, the present invention relates to a method for preventing shingles in a mammalian subject, comprising administering to said subject a composition as described above.

[0065] Suitably, a single dose of the composition is administered to the subject. Suitably, the composition is administered once.

[0066] Suitably, the composition is administered once every five years, more suitably once a year.

[0067] Suitably, the composition is administered by a route of administration selected from the group consisting of subcutaneous, intradermal and intramuscular. Suitably, the administration is intramuscular.

[0068] In one embodiment, suitably the composition is for treating or preventing chickenpox. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0069] The inventors are using an innovative technology, viral vector vaccines, to protect against infectious diseases. They are using an approach to "re-purpose" viruses by inserting small parts of different viruses (which cause the target disease) into the viral vector backbone. These "recombinant" viral vaccines cannot replicate and do not cause disease, but can induce strong immune responses against the inserted or foreign viral segments. They have demonstrated that viral vector vaccines are safe and can effectively induce immune responses in older adults and immunocompromised (HIV-infected) individuals, both important populations at risk for developing shingles.

[0070] Here we teach viral vector vaccines against VZV, the underlying causative agent in varicella zoster, and have tested these vaccines and shown that they can induce immune responses in appropriate models.

[0071] Recent data in the art suggest that a newly developed vaccine against shingles (Shingrix™-adjuvant protein) may induce protective efficacy against shingles when administered as repeated immunizations. Unfortunately, the primary use of adjuvants (i.e., to induce a strong immune response) can result in adverse responses, which is a challenge in the art. Advantageously, the viral vector vaccine of the present invention can similarly induce a strong immune response while showing limited or minimal adverse responses after vaccination.

[0072] The present inventors have generated viral vector vaccines against VZV and tested the ability of these vaccines to induce immune responses in appropriate models.

[0073] The present inventors teach various vaccination regimens to induce strong and long-lasting immunity against VZV.

[0074] The present inventors have generated a VZV vaccine and vaccination trials have demonstrated stronger cell-mediated immunity (CMI) than is achieved by currently licensed vaccines known in the art.

[0075] As used herein, the term "about" means ±1% of the given value.

[0076] The present invention provides vectors (suitably viral vectors, most suitably adenoviral vectors), compositions and formulations (e.g. pharmaceutical compositions, such as medicaments, e.g. vaccines) suitable for inducing an immune response, suitably a T cell mediated immune response, against Varicella Zoster Virus (VZV) in a vertebrate subject (suitably a mammal, more suitably a primate, most suitably a human).

[0077] Suitably, the immune response comprises a cell-mediated response.

[0078] Suitably the immune response comprises cell mediated immunity (CMI).

[0079] Suitably the immune response comprises the induction of CD4+ T cells.

[0080] Suitably, the immune response includes the induction of a CD4+ cytotoxic T cell (CTL) response.

[0081] In one embodiment, the immune response includes both a humoral response and a cell-mediated response.

[0082] Suitably the immune response comprises protective immunity.

[0083] Suitably, a vector of the invention comprises a nucleic acid having a polynucleotide sequence encoding one or more epitopes of a desired antigen, hi one embodiment, a vector of the invention suitably comprises a nucleic acid having a polynucleotide sequence which is the complement of a nucleotide sequence encoding one or more epitopes of a desired antigen.

[0084] Suitably, the one or more epitopes are T cell epitopes. Suitably, the one or more epitopes are CD4+ T cell epitopes. Suitably, the one or more epitopes are CD8+ T cell epitopes. Suitably, the one or more epitopes include at least one CD4+ T cell epitope and at least one CD8+ T cell epitope.

[0085] Suitably, a vector of the invention comprises a nucleic acid having a polynucleotide sequence encoding a CD4 T cell epitope of GlyE.

[0086] Suitably, a vector of the invention comprises a nucleic acid having a polynucleotide sequence encoding a CD8 T cell epitope of GlyE.

[0087] Suitably, a vector of the invention comprises a nucleic acid having a polynucleotide sequence encoding both the CD4 and CD8 T cell epitopes of GlyE.

[0088] Suitably the vector is used to induce both a CD4 and a CD8 T cell response to GlyE (particularly in humans), most suitably to induce both a CD4 and a CD8 T cell response to GlyE (particularly in humans) in addition to antibodies.

[0089] This further distinguishes the ChAd vaccine of the present invention from the prior art, such as Shingrix, and further illustrates other properties of the present invention which are distinctive and improved over the prior art.

[0090] Adenoviral vectors have a DNA genome, therefore the nucleic acid is suitably DNA, most suitably dsDNA.

[0091] Suitably the adenoviral vector is of monkey or human origin, suitably the adenoviral vector is of chimpanzee or human origin, suitably the adenoviral vector is of chimpanzee origin.

[0092] Suitably the nucleotide sequence is a DNA sequence.

[0093] In one embodiment, we provide glycoprotein E, one of the major VZV surface antigens, cloned into the ChAdOx1 viral vector backbone. Expression is driven by the long CMV promoter. To our knowledge, the use of chimpanzee-derived viral vector vaccines to enhance immune responses to VZV gpE has not been done before. Crucially, we also demonstrated that viral vector vaccines are safe and can effectively induce immune responses in older adults and immunocompromised (HIV-infected) individuals, both important populations at risk for developing shingles.

[0094] Shingles (herpes zoster) and chickenpox (varicella) As mentioned above, shingles (sometimes called "herpes zoster") is caused by the varicella zoster virus (VZV), the same virus that causes chickenpox. Most people get chickenpox during childhood, but after the disease resolves, the varicella zoster virus remains inactive (dormant) in the nervous system. The immune system stops the virus, but VZV can reactivate later in life and cause shingles.

[0095] Without wishing to be bound by theory, it is not well understood why the varicella zoster virus reactivates later in life, but it is thought that in most cases it is caused by a weakened immune system.

[0096] More specifically, infection with Varicella Zoster Virus (VZV), an alphaherpesvirus, is associated with two distinct diseases, chickenpox and herpes zoster. Primary infection results in chickenpox (varicella), a generally mild, self-limited disease that is usually acquired during childhood or adolescence and affects almost all individuals. After the initial primary infection with VZV, the virus remains latent in the dorsal root ganglia. It is postulated that the latent virus can frequently reactivate and replicate asymptomatically. These episodes of transient asymptomatic viremia result in repeated antigenic stimulation of immunity without clinical symptoms of disease. However, in some individuals, reactivation and replication of the latent virus results in the clinical manifestation of herpes zoster (HZ), often referred to as varicella zoster. HZ is characterized by a unilateral vesicular rash with a dermatomal distribution that generally corresponds to the skin area innervated by a single spinal or cranial sensory ganglion. Typically, the vesicles crust over in 7-10 days, but healing may take up to a month. One of the most prominent clinical symptoms of HZ is pain, which is thought to be due to VZV-induced nerve destruction and inflammation. HZ-associated pain can occur in three periods: before the onset of the skin rash (prodromal pain, typically starting 3-5 days before the appearance of skin lesions); during the acute rash period (acute neuritis) and after healing of the acute skin lesions; and beyond skin healing for an extended period of time (postherpetic neuralgia (PHN)). PHN is the most severe sequela of HZ, occurring in 10-20% of HZ patients and is described by the following characteristic pattern of constant pain described as burning, throbbing, or aching pain; intermittent sharp, stabbing, shooting, or stabbing pain; and a characteristic pattern in which most patients experience stimulus-induced pain as allodynia, which usually persists beyond the duration of the stimulus. Allodynia is present in at least 90% of PHN patients and is typically described as the most distressing and debilitating component of HZ.

[0097] Although the mechanisms leading to HZ are not well understood, a predisposing factor for the development of HZ in immunocompromised individuals is aging. The incidence and severity of HZ increases from 2.5 per 1000 person-years in adults aged 20-50 years to 7.8 per 1000 person-years in adults over 60 years. Furthermore, complications such as PHN, which are relatively infrequent in otherwise healthy children and young adults, occur in almost half of older individuals. The age-related increase in risk of HZ in otherwise healthy elderly subjects is presumed to be due to immunosenescence, which correlates with a decline in cell-mediated immunity (CMI) but not with the levels of circulating VZV-specific serum antibodies. However, studies performed in immunocompromised patients have shown that low or absent CMI is a necessary but not sufficient condition for the development of HZ.

[0098] Viral Vectors Suitably, the viral vector (sometimes referred to as "the vector") is an adenoviral vector.

[0099] Suitably, said coding sequence is present in an adenovirus-based vector, in other words, suitably, said coding sequence is present in an adenovirus vector.

[0100] Any suitable adenoviral vector may be used.

[0101] The adenoviral vector of the present invention can be any adenoviral vector suitable for use in humans.

[0102] More particularly, any replication-defective viral vector for human use may be used, preferably an adenovirus of non-human origin. For veterinary use, Ad5 may be used.

[0103] Suitably the vector may be ChAdOx1.

[0104] Suitably the vector may be ChAdOx2.

[0105] ChAdOx1 ChAdOx1 is described in WO 2012 / 172277. Briefly, ChAdOx1 is derived from the "Y25" chimpanzee adenovirus isolate. A replication-deficient vector from Y25 was obtained and deleted for E1 and E3 genes. To improve yield, some ORFs in E4 were replaced with corresponding ORFs from human adenovirus 5 (three such ORFs were replaced), which results in better yield. E4 is associated with viral replication and is believed not to affect immunogenicity / safety.

[0106] More specifically, ChAdOx1 is described in Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, et al.(2012)A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE 7(7): e40385 and WO 2012 / 172277, both of which are incorporated herein by reference, particularly for their specific teachings on the ChAdOx1 vector, such as its construction and production.

[0107] In addition, a clone of ChAdOx1 containing GFP has been deposited at the European Collection of Cell Cultures (ECACC), and AdChOX1 Bacterial artificial chromosomes (BACs) containing the cloned genome of (pBACe3.6 AdChOx1(E4 modified)TIPeGFP )A sample of E. coli strain SW1029 (a derivative of DH10B) containing AdChOx1(E4 modified)TIPeGFP, cell line name "AdChOx1(E4 modified)TIPeGFP", has been deposited under the Budapest Treaty by Isis Innovation Limited with ECACC, Health Protection Agency Culture Collections, Health Protection Agency, Porton Down, Salisbury SP4 0JG, UK on 24 May 2012 and is assigned provisional accession number 12052403. Isis Innovation Limited is the former name of the owner / applicant of this patent / application.

[0108] ChAdOx2 ChAdOx2 is described in WO 2017 / 221031. Like ChAdOx1, ChAdOx2 is derived from the C68 isolate of chimpanzee adenovirus. Again a replication-deficient virus was obtained and deleted for the E1 and E3 genes. Replacement of the three E4 ORFs, as was done for ChAdOx1, was challenging when performed for ChAdOx2. Therefore, the entire E4 region of ChAdOx2 was replaced with the engineered E4 region of ChAdOx1 (described above).

[0109] More specifically, the nucleotide sequence of the ChAdOx2 vector (with a Gateway™ cassette at the E1 position) is shown in SEQ ID NO: 5. This is a viral vector based on the chimpanzee adenovirus C68 (this is the sequence of SEQ ID NO: 10 of the priority application of GB 1610967.0 - WO 2017 / 221031).

[0110] Additionally, a clone of ChAdOx2 containing GFP has been deposited with ECACC, accession number 16061301, deposited under the Budapest Treaty at the European Collection of Cell Cultures (ECACC), Health Protection Agency Culture Collections, Health Protection Agency, Porton Down, Salisbury SP4 0JG, UK, on ​​13 June 2016 by Isis Innovation Limited, a former name of the owner / applicant of this patent / application.

[0111] Thus, ChAdOx1 and ChAdOx2 are somewhat distinct and can be used together in a heterologous prime-boost regimen (e.g., ChAdOx1 prime followed by ChAdOx2 boost or ChAdOx2 prime followed by ChAdOx1 boost). Of course, either of these vectors may also be used in a conventional heterologous prime-boost regimen, e.g., adenoviral prime followed by poxviral boost or poxviral prime followed by adenoviral boost.

[0112] The production of vaccine doses from ChAdOx1 / ChAdOx2 is identical, and therefore the techniques described herein for engineering / amplifying / preparing ChAdOx vectors are equally applicable to ChAdOx1 and / or ChAdOx2.

[0113] Although the general principles of production are the same, there will be some minor differences in the exact conditions of downstream processing due to slight differences in the charge of the virus particles, which are well within the scope of routine variation for those skilled in the art of virus production.

[0114] Briefly, the production / harvesting / purification of the viral vectors for the compositions of the invention is suitably carried out under Good Manufacturing Practice (GMP) conditions. The viral vectors of the invention may be produced in modified cell lines that contain a complement of any deleted genes necessary for viral replication. The adenoviral vectors of the invention suitably further comprise one or more modifications designed to optimize vector growth and yield in transformed cell lines, such as HEK293, that express the genes functionally deleted in the adenoviral vectors of the invention. The production of adenoviral vectors is well known in the art. In particular, the exact conditions for the production of adenoviral vectors, such as ChAdOx1 and ChAdOx2 vectors, are described in the prior art, for example in WO 2012 / 172277 or WO 2017 / 221031.

[0115] Formulation The formulation buffers for use in the clinical product are as follows:

[0116] Formulation Buffer Components 1. 10mM histidine 2. 7.5% sucrose 3. 35mM Sodium Chloride 4. 1mM Magnesium Chloride 5. 0.1% Polysorbate 80 6. 0.1mM EDTA 7. 0.5% Ethanol 8. Hydrochloric acid (to adjust the pH to approximately 6.6)

[0117] Formulated in Water for Injection according to the European Pharmacopoeia (Ph Eur).

[0118] Other formulations, such as alternative buffers, may be used, such as Merck formulation buffer A195 (10 mM Tris, 10 mM histidine, 5% sucrose, 75 mM NaCl, 1 mM MgCl2, 0.02% PS-80, 0.1 mM EDTA, 0.5% EtOH, pH 7.4).

[0119] Formulations for other routes of administration, such as aerosols, will be appropriately adjusted by the skilled operator.

[0120] Suitably the composition and / or formulation does not comprise an adjuvant.Suitably adjuvants are excluded from the composition and / or formulation of the present invention.

[0121] Antigen insertion For the insertion of the nucleotide sequence encoding the GlyE antigen, the E1 site may suitably be used, suitably with the hCMV IE promoter. Insertion into the E1 site is well within the scope of the skilled reader, who, if any guidance is required, is referred to the description of the ChAdOx1 and ChAdOx2 vectors (see above) and / or to WO 2012 / 172277 or WO 2017 / 221031. Suitably, a short or long version of the hCMV IE promoter may be used, the long version being most suitably described in WO 2008 / 122811, which is expressly incorporated herein by reference for its teachings on promoters, in particular long promoters.

[0122] If desired, it is also possible to insert the antigen at the E3 site or adjacent to the inverted terminal repeat.

[0123] antigen expression The antigen may be constitutively expressed from the viral vector. In fact, the inventors have shown that the viral vectors described herein that constitutively express antigens are stable through multiple passages. This is an advantage of the present invention. However, if desired, the expression of the antigen may be suppressed during production, which may result in better yields and / or avoid problems due to antigen toxicity. This is a matter of operator choice.

[0124] The data presented herein includes ELISPOT data showing T cell responses, which is a departure from prior art approaches where varicella zoster virus was originally focused on antibody responses.

[0125] Varicella zoster virus (VZV) In another aspect, the invention relates to a vector, composition or medicament as described herein for the treatment of a VZV infection, where "treatment" refers to the control or prevention of recurrence, e.g., from a dormant virus (sometimes referred to as an "endogenous virus" in a mammal, e.g., a primate, e.g., a human).

[0126] Suitably, the vector, composition or medicament of the invention is for controlling reactivation of VZV.

[0127] Suitably the vector, composition or medicament is for preventing recurrence of VZV infection.

[0128] Suitably the vector, composition or medicament is for controlling shingles.

[0129] Suitably the vector, composition or medicament is for preventing shingles.

[0130] advantage A drawback of prior art approaches, such as the SHINGRIX™ vaccine, is that they require two vials of material to be stored and mixed at the time of administration; in the case of SHINGRIX™, this is a vial of adjuvant and a vial of antigen, which are formulated into a single mixture at the time of administration. In contrast, the present invention advantageously requires only a single vial of material to be stored / shipped / manipulated.

[0131] Furthermore, it is an advantage of the present invention that superior immunogenicity is delivered compared to either the Zostavax or SHINGRIX™ prior art vaccines.

[0132] It is an advantage of the present invention that only a single dose is required.

[0133] It is an advantage of the present invention that only a single dose is required to induce an immune response.

[0134] It is an advantage of the present invention that the vector is safe in immunocompromised subjects.

[0135] It is an advantage of the present invention that better responses are observed compared to prior art approaches.

[0136] It is an advantage of the present invention that a T cell response, particularly a CD4+ T cell response, is generated.

[0137] It is an advantage of the invention that in some embodiments a CD8+ T cell response is also generated, in some embodiments a strong antibody response is also generated, and most importantly the invention provides the advantage of generating / boosting a CD4+ T cell response.

[0138] It is an advantage of the present invention that a strong CD8+ T cell response is generated.

[0139] A "good" single injection Ad vaccination results in a response of 100 units of SFU, with a boost typically required to exceed 1,000 SFU. Thus, appropriately, "strong" means greater than 800 SFU after one injection (single dose). Of course, the skilled reader will appreciate that this may be dose-dependent - these comments are in the context of the preferred doses given herein.

[0140] For example, even 2 weeks after a single injection of ChAdOx1-VZVGpE, 6 It is an advantage of the present invention that a strong T cell response is measured (NBELISpot measures CD4+ and CD8+ T cell responses) with a mean response of 1361 SFU per splenocyte (standard error 145 n=5). Previous studies with these viral vectors have shown lower immune responses after one-injection immunization against the variant antigen insert, for example one-injection vaccination with monovalent EBOV in preclinical models induced only 200-500 SFU - indicating that the present invention produces a much stronger response than the prior art. Furthermore, figures 1 and 2 from the prior art Dicks et al 2015 (Vaccine 33 (2015) pages 1121-1128 "The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species") show a much weaker immunogenicity, which again demonstrates the surprising strength of the response according to the present invention.

[0141] It is an advantage of the present invention that a sustained T cell response is produced. Unless the context clearly indicates otherwise, "sustained" means for at least 16 weeks.

[0142] It is an advantage of the present invention that the same vector may be used to revaccinate (i.e. boost) a patient. This may be achieved by priming with ChAdOx1 and boosting with ChAdOx2 or priming with ChAdOx2 and boosting with ChAdOx1. Furthermore, the same vector used for the prime may be used for the boost, provided that the boost is spaced at least 6 months from the prime. This may be referred to as "allogeneic prime-boost."

[0143] It is an advantage of the present invention that no adjuvant is required, thereby avoiding the disadvantages of pain / reactogenicity experienced when using adjuvants during administration to humans.

[0144] It is an advantage of the present invention that the composition is cheaper than an adjuvanted vaccine. Adjuvants are complex formulations and can be expensive, for example 20 USD per dose. The composition of the present invention is simpler and cheaper, since it only requires a single component (i.e., a viral vector containing the antigen as described), which is an advantage of the present invention.

[0145] It is an advantage of the present invention that it uses a live replication defective viral vector, and therefore the present invention is safer than the prior art, e.g. Zostavax™.

[0146] It is an advantage of the present invention that only a single dose is required, therefore making the present invention superior to the multiple dose prior art, such as Shingrix™.

[0147] It is an advantage of the present invention that only a single composition / single vial is required, making the present invention superior to the adjuvant prior art, such as Shingrix™, which requires two vials, one antigen and one adjuvant, to be shipped and stored and then mixed just prior to injection.

[0148] It is an advantage of the present invention that it has superior immunogenicity over the prior art, such as Zostavax™ or Shingrix™.

[0149] GlyE antigen "GlyE antigen" (sometimes referred to as "gE") refers to the "canonical" gE antigen sequence of VZV.

[0150] More particularly, the original VZV sequences (and strains) used to generate the compositions of the invention are suitably published coding sequences such as: Definition Human herpesvirus 3 isolate 1140 VZV glycoprotein E gene, complete cds Accession (GenBank) AY253715 Version AY253715.1: 1 atggggacag ttaataaacc tgtggtgggg gtattgatgg ggttcggaat tatcacggga 61 acgttgcgta taacgaatcc ggtcagagca tccgtcttgc gatacgatga ttttcacatc 121 gatgaagaca aactggatac aaactccgta tatgagcctt actaccattc agatcatgcg 181 gagtcttcat gggtaaatcg gggagagtct tcgcgaaaag cgtacgatca taactcacct 241 tatatatggc cacgtaatga ttatgatgga tttttagaga acgcacacga acaccatggg 301 gtgtataatc agggccgtgg tatcgatagc ggggaacggt taatgcaacc cacacaaatg 361 tctgcacagg aggatcttgg ggacgatacg ggcatccacg ttatccctac gttaaacggc 421 gatgacagac ataaaattgt aaatgtggac caacgtcaat acggtgacgt gtttaaagga 481 gatcttaatc caaaacccca aggccaaaga ctcattgagg tgtcagtgga agaaaatcac 541 ccgtttactt tacgcgcacc gattcagcgg atttatggag tccggtacac cgagacttgg 601 agctttttgc cgtcattaac ctgtacggga gacgcagcgc ccgccatcca gcatatatgt 661 ttaaaacata caacatgctt tcaagacgtg gtggtggatg tggattgcgc ggaaaatact 721 aaagaggatc agttggccga aatcagttac cgttttcaag gtaagaagga agcggaccaa 781 ccgtggattg ttgtaacac gagcacactg tttgatgac tcgaattaga cccccccgag 841 attgaaccgg gtgtcttgaa agtacttcgg acagaaaaac aatacttggg tgtgtacatt 901 tggacatgc gcggctccga tggtacgtct acctacgcca cgtttttggt cacctggaa 961 ggggatgaaa aaacaagaaa ccctacgccc gcagtaactc ctcaaccaag aggggctgag 1021 tttcatatgt ggaattacca ctcgcatgta ttttcagttg gtgatacgtt tagcttggca 1081 atgcatcttc acatgaagcg ccatttgatt tgctgttaga gtggttgtat 1141 gtccccatcg atcctacatg tcaaccaatg cggttatatt ctacgtgttt gtatcatccc 1201 aacgcacccc aatgcctctc tcatatgaat tccggttgta catttacctc gccacattta 1261 gcccagcgtg ttgcaagcac agtgtatcaa aattgtgaac atgcagataa ctacaccgca 1321 tattgtctgg gaatatctca tatggagcct agctttggtc taatcttaca cgacgggggc 1381 accacgttaa agtttgtaga tacacccgag agtttgtcgg gattatacgt ttttgtggtg 1441 tattttaacg ggcatgttga agccgtagca tacactgttg tatccacagt agatcatttt 1501 gtaaacgcaa ttgaagagcg tggatttccg ccaacggccg gtcagccacc ggcgactact 1561 aaacccaagg aaattacccc cgtaaacccc ggaacgtcac cacttctacg atatgccgca 1621 tggaccggag ggcttgcagc agtagtactt ttatgtctcg taatattttt aatctgtacg 1681 gctaaacgaa tgagggttaa agcctatagg gtagacaagt ccccgtataa ccaaagcatg 1741 tattacgctg gccttccagt ggacgatttc gaggactcgg aatctacgga tacggaagaa 1801 gagtttggta acgcgattgg agggagtcac gggggttcga gttacacggt gtatatagat 1861 aagaccggt ga

[0151] This is a coding sequence identical to the most well-known VZV strains: Human herpesvirus 3 strain Oka vaccine strain.

[0152] Suitably, GlyE has the amino acid sequence generated by translating the above coding sequence (cds) using the universal genetic code, i.e. the published amino acid sequence as follows: GenBank:AY253715.1: MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDRHKIVNVDQRQYG DVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAIQHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELLDPPEIEPGVLKVLRTEKQYLGVYIWNMRGSDGTST YATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLAMHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVD TPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYTVYIDKTR

[0153] An exemplary GlyE amino acid sequence is GenBank Accession No. AAP32865.1 - SEQ ID NO: 1. The most likely GlyE amino acid sequence is SEQ ID NO: 2.

[0154] Suitably, the GlyE antigen comprises SEQ ID NO:1 or SEQ ID NO:2.

[0155] Suitably, the GlyE antigen consists of SEQ ID NO:1 or SEQ ID NO:2.

[0156] Suitably, the GlyE antigen comprises or consists of a full length GlyE antigen, such as shown in SEQ ID NO:1 or SEQ ID NO:2.

[0157] Suitably, said GlyE antigen does not comprise any truncations / mutations / tags / linkers / fusions compared to the sequence shown in SEQ ID NO:1 or SEQ ID NO:2.

[0158] bgh polyadenylation signal The bovine growth hormone polyadenylation (bgh-PolyA) signal is a specialized termination sequence for protein expression in eukaryotic cells. This DNA sequence may be operably added to the nucleic acid sequence encoding the GlyE antigen.

[0159] An exemplary bgh polyadenylation signal has the sequence shown in SEQ ID NO:6.

[0160] Suitably, expression of the antigen is controlled by a standard promoter, such as the "long CMV" promoter. The sequence of an exemplary "long CMV" promoter is shown in SEQ ID NO:7.

[0161] use Suitably the method is a method of immunisation.

[0162] In one aspect, the present invention relates to a composition comprising an adenoviral vector, wherein said adenoviral vector comprises GlyE.

[0163] Suitably, the composition does not include an adjuvant. Adjuvants may cause reactogenicity, particularly in primates, such as humans. It is therefore advantageous that the composition of the present invention is effective without an adjuvant. Suitably, an adjuvant is excluded. Suitably, the composition consists of elements other than an adjuvant. Suitably, an adjuvant is specifically excluded from the composition of the present invention. Suitably, the composition is an adjuvant-free composition.

[0164] The present invention may be used to prevent primary VZV infection that causes chickenpox in children and other susceptible individuals.

[0165] In another aspect, the present invention relates to the use of the above composition in medicine.

[0166] In another aspect, the present invention relates to the use of the above composition in the preparation of a medicament for VZV infection. Suitably, said medicament is for controlling VZV infection. Suitably, said medicament is for preventing recurrence of VZV infection. Suitably, said medicament is for controlling shingles. Suitably, said medicament is for preventing shingles.

[0167] In another aspect, the invention relates to a method of inducing an immune response in a subject, said method comprising administering to said subject a composition as described above.

[0168] Suitably, the immune response comprises cell mediated immunity. Suitably, the immune response comprises a T cell response. Suitably, the T cell response comprises a CD4+ T cell response.

[0169] In another aspect, the invention relates to a method comprising administering a first composition comprising an adenovirus-based vector and a second composition comprising an adenovirus-based vector.

[0170] In another aspect, the invention relates to a method comprising administering a first composition comprising a first adenovirus-based vector and a second composition comprising a second adenovirus-based vector.

[0171] Suitably the composition and the second composition are different.

[0172] Most suitably, the first adenovirus based vector and the second adenovirus based vector are different.

[0173] Suitably, the subject is a mammal.

[0174] Suitably, the subject is a primate.

[0175] Suitably, the subject is a human.

[0176] The present invention also relates to the use of a vector, composition or medicament described herein for treating a VZV infection.

[0177] The present invention also relates to the use of a vector, composition or medicament described herein for controlling VZV infection.

[0178] The present invention also relates to the use of a vector, composition or medicament described herein for controlling a dormant VZV infection.

[0179] The present invention also relates to the use of a vector, a composition or a medicament described herein for preventing VZV infection.

[0180] The present invention also relates to the use of a vector, a composition or a medicament as described herein for preventing recurrence of VZV infection.

[0181] composition Suitably the composition is an antigenic composition.

[0182] Suitably the composition is an immunogenic composition.

[0183] Suitably the composition is a vaccine composition.

[0184] Suitably the composition is a pharmaceutical composition.

[0185] Suitably the composition is formulated for administration to a mammal, suitably a primate, most suitably a human.

[0186] Suitably, the composition is formulated with its route of administration in mind. Suitably, the composition is formulated to be suitable for the particular route of administration. Suitably, the composition is formulated to be suitable for the route of administration selected by the operator or physician.

[0187] It is an advantage of the present invention that the composition does not require an adjuvant. Suitably, the composition of the present invention for administration advantageously does not include an adjuvant. Suitably, adjuvants are omitted from the composition of the present invention. Most suitably, adjuvants are excluded from the composition of the present invention. Most suitably, the composition of the present invention is adjuvant-free.

[0188] Administration In principle, any suitable route of administration may be used.

[0189] Suitably, the composition is administered by a route of administration selected from the group consisting of intranasal, oral, aerosol, subcutaneous, intradermal and intramuscular.

[0190] More suitably, the composition is administered by a route of administration selected from the group consisting of subcutaneous, intradermal and intramuscular.

[0191] Most suitably, said administration is intramuscular.

[0192] Suitably, the compositions of the invention are administered intramuscularly.

[0193] Suitably, the compositions of the present invention are formulated for intramuscular administration.

[0194] Suitably, the compositions of the invention are administered as a single dose.

[0195] dose It should be noted that there are alternative ways of describing the dosage of an adenoviral vector.

[0196] Viral Particles - vp / mL. This refers to the count of total viral particles administered.

[0197] Infectious Units - iu / mL. This refers to the number of infectious units administered and may correlate more accurately with immunogenicity.

[0198] Traditionally, clinical trials in the UK have tended to present doses in terms of viral particles.

[0199] A typical range is 1x10 7 vp~1x10 11 vp or 1x10 8 vp~5x10 11 More preferably, the single dose will be 5×10 per administration for an adult human. 8 ~5×10 10 in the range of viral particles, more appropriately 5 × 10 per dose 9 ~5×10 10 in the range of viral particles, more appropriately 2.5 × 10 per dose 10 ~5×10 10 It is in the range of virus particles.

[0200] Most suitably, the dose is 2.5×10 per dose for an adult human. 10 virus particles or approximately this value.

[0201] Suitably, the pediatric dose will be determined by a physician with reference to the advice given herein for the adult dose. Exemplary pediatric dose = 1 / 2 adult dose or 1x10 10 vp / child.

[0202] Infectious units depend on the P:I ratio (viral genome:infectious particle ratio) for any given formulation, as is known in the art.

[0203] Suitably, no adjuvant is administered with the viral vector of the invention.

[0204] Suitably, the viral vectors of the invention are formulated with a simple buffer. Exemplary buffers may be set out below under the heading "Formulation".

[0205] Suitably the composition is administered as a single dose.

[0206] As used herein, "adult" means a subject who is at least 18 years of age.

[0207] As used herein, "child" refers to a subject under the age of 18.

[0208] Suitably the compositions of the invention may be administered to subjects aged 2 years or older, suitably 18 years or older, suitably 60 years or older, suitably 70 years or older, suitably 79 years or older.

[0209] Dosage can typically be determined by a physician taking into account factors such as age, weight, sex or other relevant considerations. Dosages given herein are exemplary doses. Unless otherwise stated, all doses are for "adult" subjects, and pediatric doses can be determined therefrom, for example, pediatric doses can be 50% of adult doses, or more appropriately pediatric doses are as described herein.

[0210] Database Release Sequences deposited in a database may change over time, and where appropriate the current version of the sequence database is relied upon, or the release in effect at the time of filing.

[0211] As one of skill in the art knows, the accession number may be a version / date accession number. Citable accession numbers for current database entries are the same as above, excluding decimals and any trailing digits.

[0212] GenBank is the NIH gene sequence database, an annotated collection of all publicly available DNA sequences (National Center for Biotechnology Information, National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA; Nucleic Acids Research, 2013 Jan;41(D1):D36-42), to which the accession numbers given relate unless otherwise indicated. Where appropriate, the GenBank database release referred to is NCBI-GenBank Release 223.0 of December 15, 2017.

[0213] UniProt (Universal Protein Resource) is a comprehensive directory of information about proteins ("UniProt: a hub for protein information", Nucleic Acids Res. 43: D204-D212(2015)). For the avoidance of doubt, UniProt release 2015_11 is authoritative.

[0214] More specifically, the UniProt Knowledgebase (UniProtKB) release 2018_01 (31 January 2018) of the UniProt consortium EBI (European Bioinformatics Institute), SIB (Swiss Institute of Bioinformatics) and PIR (Protein Information Resource) is relied upon.

[0215] Applicable The composition of the present invention can be used as a chickenpox vaccine, most suitably in children.Accordingly, the present invention relates to the use of said composition for preventing chickenpox.In this embodiment, the composition is administered to infants and / or children and / or adults in at least one dose, suitably said administration is performed before exposure to generate a protective immune response.

[0216] The compositions of the invention may be used as vaccines in immunocompromised children. In the prior art, children receive lower doses of Zostavax™ than adults.

[0217] It has been sometimes disclosed in the art that adenovirus can be used as a prime followed by poxvirus as a boost. However, according to the present invention, applying a vaccine to an individual who has been previously exposed to VZV means that said individual may have a pre-existing response (e.g., a pre-existing immune response to VZV). "Pre-existing response" appropriately means that the individual has been previously exposed to VZV, which is typically assessed by measuring seroconversion to VZV surface antigens.

[0218] The UK National Health Service (NHS) states: "You can have a blood test to see if you have antibodies to the disease, which will prove you have had chickenpox before" https: / / www.nhs.uk / conditions / vaccinations / when-is-chickenpox-vaccine-needed / #how-to-check-if-youve-had-chickenpox-before.

[0219] Thus, if a patient has been previously exposed to VZV, administration of a vaccine according to the present invention may be considered as a boost. Thus, essentially, the present invention may be considered to teach the use of adenoviral vectors as a boost, which departs from the prior art teaching that poxvirus vectors are best suited for boosting.

[0220] VZV from an earlier infection (e.g., chickenpox in childhood) may remain dormant in a patient's body, e.g., nervous system, and may re-emerge as shingles later in life. A "dormant" VZV infection may be defined as one that no longer causes active infection.

[0221] In one embodiment, the invention relates to a composition for administration to a mammal, comprising an adenoviral vector as described above.

[0222] Further Applications In one aspect, the present invention relates to a viral vector comprising a nucleic acid having a polynucleotide sequence encoding at least one epitope of a Varicella-Zoster virus (VZV) GlyE antigen, wherein said viral vector is an adenoviral vector of human or simian origin.

[0223] In one aspect, the present invention relates to a viral vector comprising a nucleic acid having a polynucleotide sequence encoding at least one CD4 T cell and one CD8 T cell epitope of a Varicella-Zoster Virus (VZV) GlyE antigen, wherein said viral vector is an adenoviral vector of human or simian origin.

[0224] In one aspect, the invention relates to the use of the above-mentioned composition in the preparation of a medicament for inducing both a CD4+ and a CD8+ T cell response against the GlyE antigen in a vaccinated subject.

[0225] In one aspect, the present invention relates to the use of the above composition in the preparation of a medicament for inducing both CD4+ and CD8+ T cell responses against a GlyE antigen in a vaccinated subject, wherein said subject is a human.

[0226] In one aspect, the present invention relates to the use of the above composition in the preparation of a medicament for inducing both CD4+ and CD8+ T cell responses and antibodies against the GlyE antigen in a vaccinated subject, wherein the subject is a human.

[0227] Further benefits One focus of the present invention is to provide the gE antigen in the context of an adenovector, such as the ChAdOx vector.

[0228] Here we present data showing the efficacy of the ChAdOx-gE construct, which we compare to the existing Zostavax™ and demonstrate the superiority of the construct of the present invention.

[0229] These excellent results are better than could be expected based on the known properties of the ChAdOx vector in the art and / or information about the gE antigen (this combination has not been disclosed in the art).

[0230] In particular, the inventors teach that their constructs are surprisingly effective and / or that prejudices in the art frown upon the use of the constructs and / or that these constructs are obscure / cryptic / special.

[0231] Adenoviral vectors are typically used in the art for priming immunization, whereas poxvirus vectors are typically used for boosting applications. It can be observed that we actually teach the use of adenoviral vectors for boosting in the present invention, because most people already have some pre-existing T cell response from past infection with varicella zoster virus (VZV). This has not been done before for varicella zoster virus (VZV). Thus, in one embodiment, the present invention relates to a method for enhancing a pre-existing immune response to VZV in a mammal by administering the composition described above to said mammal. In one embodiment, the present invention relates to the composition described above for use in enhancing a pre-existing immune response to VZV in a mammal. Whether a mammal has a pre-existing immune response to VZV can be determined by evaluating seroconversion to VZV surface antigens, as described above.

[0232] Important demonstration of the improvements delivered by the present invention is based on data such as the efficacy data presented herein.

[0233] In this regard, the inventors have generated superior T cell responses with the vectors of the present invention. The existing Zostavax™ vaccine focuses on antibody responses. Thus, the present invention is a measurable improvement over the art.

[0234] The single dose of adenovirus described herein has the additional (and unexpected) advantage of generating a robust humoral response as a protein and adjuvant, which is a measurable improvement over the art. [Brief description of the drawings]

[0235] [Figure 1] The plot. [Diagram 2] This is a bar graph. [Diagram 3] This is a graph. [Figure 4] The plot. [Figure 5-1] ~ [Figure 5-5] FIG. 1 shows sequence comparison. "Insert" refers to SEQ ID NO: 4 (i.e., an exemplary nucleotide sequence encoding the antigen cassette). "AY253715.1" refers to SEQ ID NO: 3 (i.e., the wild-type nucleotide sequence encoding the GlyE antigen). [Figure 6-1] ~ [Figure 6-3] FIG. 1 shows sequence comparison (CLUSTAL O(1.2.4) multiple sequence comparison). "Vaccine" refers to SEQ ID NO:2 (i.e., an exemplary VZV GlyE amino acid sequence antigen cassette). "AY253715.1" refers to SEQ ID NO:1 (i.e., the wild-type VZV GlyE amino acid sequence). [Figure 7] Here is a photo. [Figure 8] Plots and graphs. [Figure 9] There are four graphs. [Figure 10] This is a graph. [Figure 11] Graph and two plots. [Figure 12] This is a bar graph. [Figure 13] This is a bar graph. [Figure 14] The plot. [Figure 15] The plot.

[0236] [Example] Example 1

[0237] Viral vector vaccine against VZV We have generated a viral vector vaccine against VZV, and our data suggest that the vaccine of the present invention is superior to the conventional licensed prior art varicella zoster vaccines that have been preclinically evaluated for CMI (Figure 1).

[0238] The higher CMIs routinely achieved with viral vector vaccines are likely to translate into higher efficacy when compared to other vaccine modalities, and at the same time efficacy may be claimed for viral vector vaccines that advantageously require only a single injection, as opposed to the repeated administration of known protein vaccines in adjuvants.

[0239] Please refer to Figure 1.

[0240] Groups of Balb / c mice (n=5) were cultured at 1x10 7 IU of ChAdOx1-VZVgpE or 1x10 7 IU of ChAdOx2-VZVgpE or 1.3x10 3 Mice were vaccinated intramuscularly with pfu of Zostax. Two weeks after the final vaccination, splenocytes were harvested and cellular immune responses to peptides spanning glycoprotein E were measured by ELISpot analysis.

[0241] Responses after ChAdOx1-VZV-gE were significantly higher than after Zostavax.

[0242] This study was in young mice, approximately 8 weeks of age or older.

[0243] It is noted that the prior art Zostavax vaccine can replicate in humans, and without wishing to be bound by theory, may result in partial immunogenicity enhancement.However, it has been demonstrated that the non-replicating Zostavax vaccine is comparable to replicating Zostavax in terms of immunogenicity measured in humans, and can induce the same immune response.

[0244] In any case, this is a fair test since none of the vaccines used replicate in mice, thus demonstrating that the present invention is superior to the prior art, Zostavax.

[0245] Please refer to Figure 2.

[0246] 8 week+ or aged post-breed female Balb / c mice were vaccinated intramuscularly with 1.00E+07iu of ChAdOX1-VZV-gE. Mice were culled approximately 2 weeks later and spleen ELISpot was performed with a peptide spanning the entire VZV gE insert.

[0247] Responses following ChAdOx1-VZV-gE were not significantly different.

[0248] This study was in aged mice.

[0249] Please refer to Figure 3.

[0250] 8 week+ old female Balb / c mice were vaccinated intramuscularly with: ChAdOX1-VZV-gE-group 1. 1.00E+07iu ChAdOX1-VZV-gE 4 weeks later, boosted with 1.00E+07iu ChAdOX1-VZV-gE; ChAdOX2-VZV-gE-group 2. 1.00E+07iu ChAdOX2-VZV-gE 4 weeks followed by a boost with 1.00E+07iu ChAdOX2-VZV-gE. Zostavax group 3. VZV Zostavax at 1.29E+03 4 weeks followed by a boost with VZV Zostavax at 1.29E+03. Serum was collected at the indicated time points and assayed for anti-VZV-gpE specific antibodies.

[0251] The inventors note that Kruskal-Wallis analysis with Dunn's multiple comparison test indicates that there is a significant difference in the response between groups 2 and 3 at 2 weeks post-boost, but not between groups 1 and 3. This may represent an additional advantage of this particular embodiment in which the vector is ChAdOx1, i.e., the inventors did not expect to see antibody responses comparable to Zostavax (as evidenced by group 2-ChAdOx2), but group 1 (ChAdOx1 embodiment) surprisingly generates a good antibody response as well as a good T cell response.

[0252] We note that there is no significant difference in antibody responses at 2 weeks or 16 weeks after a single injection, as shown in FIG.

[0253] With reference to FIG. 4, 8 week+ old female Balb / c mice were vaccinated intramuscularly with: Lane 1. 1.00E+07iu ChAdOX1-VZV-gE 1 week followed by boost with 1.00E+07iu ChAdOX1-VZV-gE (black square). Lane 1. 1.00E+07iu of ChAdOX1-VZV-gE 1 week followed by boost with 1.00E+07iu of ChAdOX2-VZV-gE (filled circle). Lane 2. 1.00E+07iu ChAdOX1-VZV-gE 4 weeks later, boosted with 1.00E+07iu ChAdOX1-VZV-gE (black square). Lane 2. 1.00E+07iu ChAdOX1-VZV-gE 4 weeks later, boosted with 1.00E+07iu ChAdOX2-VZV-gE (filled circle). Lane 3 (no boost). 1.00E+07iu of ChAdOX1-VZV-gE (open circle).

[0254] Mice were culled approximately 2 weeks later and a splenic ELISpot was performed with a peptide spanning the entire VZV gE insert.

[0255] Thus, lane 3 (no boost) represents the "single injection" scheme; lanes 2 and 3 "filled squares" represent the "homologous prime-boost" scheme; lanes 2 and 3 "filled circles" represent the "heterologous prime-boost" scheme. It may be considered that the second heterologous injection shows no boost, although boost at later time points may be expected - this may be due to a response curve effect.

[0256] Responses following ChAdOx1-VZV-gE were not significantly different in young or old animals following single dose application.

[0257] The preferred interval between prime and boost (in prime-boost applications, the single dose embodiment is generally preferred) is 4 weeks, and when both prime and boost are Ad vectors the interval may be, for example, 2, 4, 6 or 8 weeks.

[0258] Mouse model systems It should be noted that for the mouse model system for testing these vaccines, non-replicating varicella zoster virus can produce a response comparable to replicating varicella zoster virus in humans.Thus, the mouse data presented herein represents a fair comparison, since the prior art Zostavax™ does not induce limited infection in humans, which is important for enhancing immune response, but neither the adenoviral vector construct of the present invention nor the Zostavax prior art comparison standard replicates in mice, and therefore the data presented in this application compared to the formulation in mice is fair and shows the superior properties of the vector according to the present invention. Example 2

[0259] The vectors of the present invention are efficiently expressed We show Western blot analysis of viral vector expression of VZVgpE. Subconfluent HEK293T (ChAdOx1) were infected with virus at the indicated MOI. Cells were harvested and lysed 18 hours later, and protein supernatant lysates were run on a Biorad 4-12% gradient gel and labeled with Abcam 52549 VZV at 1:1000 dilution in 0.05% PBST, and expression was detected with ECL reagent.

[0260] The results are shown in FIG. 7, the lanes are as follows: 0 - molecular markers 1-ChAdOx1 VZVgpE MOI1 on HEK293T 2 -ChAdOx1 VZVgpE MOI5 on HEK293T 3 -ChAdOx2 VZVgpE MOI1 on HEK293T 4 -ChAdOx2 VZVgpE MOI5 on HEK293T 5 - VZV+ve control ~ 100ng 6 - VZV+ve control ~ 500ng

[0261] Thus, the compositions of the invention are demonstrated to produce antigen expression in human cells. Example 3

[0262] Immunogenicity of viral vectors encoding varicella-zoster virus glycoprotein E Demonstrate cellular immunogenicity following single injection vaccination against VZV.

[0263] See Figure 8A. Groups of Balb / c mice (n=5) were cultured at 1x10 7 IU of ChAdOx1-VZVgpE or 1x10 7 IU of ChAdOx2-VZVgpE or 1.3x10 3 Mice were vaccinated intramuscularly with pfu of Zostax. Two weeks after the final vaccination, splenocytes were harvested and cellular immune responses to peptides spanning glycoprotein E were measured by ELISpot analysis.

[0264] See Figure 8B. Groups of Balb / c mice (n=5, typically 8-10 weeks old unless otherwise indicated) were cultured at 1x10 7 IU of ChAdOx1-VZVgpE ("old mice" are post-breeding and typically over 24 weeks of age) or 1.3x10 3 Mice were vaccinated intramuscularly with pfu of Zostax. Splenocytes were harvested at the indicated time points after the final vaccination and cellular immune responses to peptides spanning glycoprotein E were measured by ELISpot analysis.

[0265] These ELISpot data show that a cellular immune response is induced by the present invention, as demonstrated by the T cell response. The response is evident at 2 weeks. The response is induced by a single administration. The response is induced by a single dose. The response is a sustained response, as shown by the data at 16 weeks.

[0266] See Figure 9. The cellular immune response of the same group of Balb / c mice as in Figure 8 was assessed by Intracellular Cytokine Staining (ICS). As before (n=5, typically 8-10 weeks old unless otherwise indicated), 1x10 7 IU of ChAdOx1-VZVgpE ("old mice" are post-breeding and typically over 24 weeks of age) or 1.3x10 3 Mice were vaccinated intramuscularly with pfu of Zostax. Splenocytes were harvested at the indicated time points after the final vaccination and cellular immune responses to epitopes spanning glycoprotein E were measured by ICS analysis.

[0267] FIG. 9A shows the percentage of CD8+ T cells secreting IFN-γ following stimulation with VZVgpE peptide, adjusted for background levels of secretion.

[0268] FIG. 9B shows the percentage of CD4+ T cells secreting IFN-γ following stimulation with VZVgpE peptide, adjusted for background levels of secretion.

[0269] FIG. 9C shows the percentage of IFN-γ+CD8+ T cells secreting TNFα and / or IL2 following stimulation with VZVgpE peptides, adjusted for background levels of secretion.

[0270] FIG. 9D shows the percentage of IFN-γ+CD4+ T cells secreting TNFα and / or IL2 following stimulation with VZVgpE peptides, adjusted for background levels of secretion.

[0271] So overall these FACS sorting studies show that triple secreting CD4+ T cells (very good, as this is believed to be the most protective without wishing to be bound by theory) are induced by the present invention. The data also show induction of CD8+ T cells, which is also very informative.

[0272] See Figure 10, which shows humoral immunity after a single injection vaccination against VZV. Groups of Balb / c mice (n=5, 8-10 weeks old unless otherwise indicated) were vaccinated with 1x10 7 IU of ChAdOx1-VZVgpE ("old mice" are post-breeding and typically over 24 weeks of age) or 1.3x10 3 Mice were vaccinated intramuscularly with pfu of Zostax. Sera were collected at the indicated time points after the last vaccination, and humoral immune responses to affinity-purified glycoproteins of Varicella Zoster Virus (Ellen strain) were measured by ELISA.

[0273] Note that for clarity, Figures 8B, 9 and 10 show data from the same study.

[0274] It is a surprising advantage that immunization according to the invention is also effective in raising / inducing antibody titers despite being administered as a single injection. It is a surprising advantage that the present invention is as good as prior art compositions, such as Zostavax, in inducing an antibody response. Example 4

[0275] Prime-boost testing 1 shows immunogenicity following prime-boost vaccination against VZV.

[0276] Please refer to Figure 11A.

[0277] 8 week+ old female Balb / c mice were vaccinated with: ChAdOX1-VZV-gE-group 1. 1.00E+07iu ChAdOX1-VZV-gE 4 weeks followed by a boost with 1.00E+07iu ChAdOX1-VZV-gE ChAdOX2-VZV-gE-group 2. 1.00E+07iu ChAdOX2-VZV-gE 4 weeks followed by a boost with 1.00E+07iu ChAdOX2-VZV-gE Zostavax- Group 3. VZV Zostavax at 1.29E+03 4 weeks followed by a boost with VZV Zostavax at 1.29E+03. Serum was collected at the indicated time points and assayed for anti-VZV-gpE specific antibodies.

[0278] Referring to FIG. 11B and FIG. 11C, groups of Balb / c mice (n=5, 8-10 weeks old unless otherwise indicated) were cultured at 1×10 7 Vaccination was performed intramuscularly with 1x10 IU of ChAdOx1-VZVgpE and either not boosted (no boost) or 1 or 4 weeks later, 7 IU of ChAdOx1-VZVgpE (allogeneic boost) or 1x10 7 Boosting was performed with IU of ChAdOx2-VZVgpE (heterologous boost). a. Splenocytes were harvested 2 weeks after the final vaccination and cellular immune responses to peptides spanning glycoprotein E were measured by ELISpot analysis. b. Sera were collected 2 weeks after the final vaccination and humoral immune responses against affinity purified glycoproteins of Varicella Zoster Virus (Ellen strain) were measured by ELISA.

[0279] These data show that the single injection or single dose embodiment of the present invention provides a good response comparable to the prime-boost regimen. Thus, it is an advantage of the present invention that only a single injection or single dose (single administration) is required. Example 5

[0280] Comparative Test The inventors compare the composition of the present invention with the prior art Shingrix™ over three doses and after a single injection.

[0281] Humoral immunity after one injection vaccination against VZV was examined. Groups of CD1 mice (n=7 / 8) were vaccinated intramuscularly with either ChAdOx1-VZVgpE or Shingrix™ at the indicated doses (3 doses). Sera were collected 4 weeks after the indicated vaccinations and humoral immune responses against affinity purified glycoproteins of Varicella Zoster Virus (Ellen strain) were measured by ELISA. See Figure 12. Means are shown with standard errors.

[0282] [Table 1]

[0283] Cellular immunogenicity after one-injection vaccination against VZV was examined. Groups of CD1 mice (n=7 / 8) were vaccinated intramuscularly with either ChAdOx1-VZVgpE or Shingrix™ at the indicated doses (3 doses). Splenocytes were harvested 4 weeks after the final vaccination and cellular immune responses against peptides spanning glycoprotein E were measured by ELISpot analysis. See Figure 13. Means are shown with standard errors.

[0284] [Table 2] Example 6

[0285] Comparative Test Groups of outbred CD-1 mice (n=8) were vaccinated intramuscularly with: Group 1; 1 μg Shringrix with ASO1B adjuvant, animals were boosted 4 weeks later with 1 μg Shringrix with ASO1B adjuvant, or Group 2: No prime, 4 weeks later animals were 1.3x10 3 Vaccinated with pfu Zostavax or Group 3; 1.3x10 3pfu Zostavax, 4 weeks later animals were 1x10 7 boosted with IU of ChAdOx1-VZVgpE, or Group 4: No prime, animals were 1x10 7 vaccinated with IU of ChAdOx1-VZVgpE, or Group 5: naive animals.

[0286] See Figure 14. Means and standard errors of the means are depicted.

[0287] Serum was collected approximately 3 weeks after the final vaccination and analyzed for anti-VZVgpE antibodies.

[0288] Kruskal-Wallis analysis with Dunn's multiple comparison test shows that group 1, two injections of the protein with adjuvant, induces significantly higher antibody titers when compared to group 2, one injection of Zostavax or group 4, one injection of ChAdOx1-VZVgpE, which is expected. However, there was no difference in the antibody levels measured between group 1 and group 3. This is unexpected, as ChAdOx1 followed by Zostavax would not be expected to boost humoral immunity to a level comparable to two injections of the adjuvant protein. This is an advantage, as currently, UK adults aged 70 years or older are recommended to receive Zostavax vaccination, and here we demonstrate that boost vaccination with ChAdOx1-VZV-gpE can boost antibody titers to levels measured after vaccination with two proteins and an adjuvant, a regimen associated with an efficacy of 91% or more.

[0289] [Table 3] Example 7

[0290] Comparative Test Groups of C57BL6 mice (n=5) were vaccinated intramuscularly as follows: Group 1; 1 μg Shringrix with ASO1B adjuvant, animals were boosted 4 weeks later with 1 μg Shringrix with ASO1B adjuvant, or Group 2: No prime, 4 weeks later animals were 1.3x10 3 Vaccinated with pfu Zostavax or Group 3; 1.3x10 3 pfu Zostavax, 4 weeks later animals were 1x10 7 boosted with IU of ChAdOx1-VZVgpE, or Group 4: No prime and 4 weeks later animals were 7 They were vaccinated with IU of ChAdOx1-VZVgpE.

[0291] See Figure 15. Means and standard errors are depicted.

[0292] Splenocytes were harvested approximately 4 weeks after the final vaccination and analyzed for NK maturation and cytokine secretion. Kruskal-Wallis analysis with Dunn's multiple comparison test showed a mean mean of 1.3x10 3 1x10 after Zostax in pfu 7 Figure 2 demonstrates that NK cells following IU ChAdOx1-VZVgpE prime-boost vaccination secrete more IFN-g (group 3) when compared to Shringix vaccination (group 1).

[0293] This is unexpected and offers an advantage, as NK cell activation has previously been shown to enhance adaptive immune responses, and this strong induction of innate immune responses by ChAdOx1-VZVgpE after Zostavax prime is unexpected. Furthermore, NK cells have been shown to be critically important in mediating immunity to VZV infection (PMID; 2543925, 30565241).

[0294] [Table 4]

[0295] Note that "GlyE" stands for glycoprotein E, which is sometimes referred to as "gE."

[0296] In one embodiment, a GlyE sequence may be used which has 50% or less similarity to the antigen insert SEQ ID NO: 1. In one embodiment, a GlyE sequence may be used which has 50% or more similarity to the antigen insert SEQ ID NO: 1, suitably 60% or more, suitably 70% or more, suitably 80%, suitably 90% or more, suitably 95% or more similarity to the antigen insert SEQ ID NO: 1. [Sequence List Free Text]

[0297] SEQ ID NO:1: Exemplary GlyE sequence - GenBank Accession No. AAP32865.1 - (>AAP32865.1 Glycoprotein E [Human Alphaherpesvirus 3]) (also known as the amino acid sequence encoded by GenBank Nucleotide Accession No. AY253715.1): MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDRHKIVNVDQRQYG DVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAIQHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELLDPPEIEPGVLKVLRTEKQYLGVYIWNMRGSDGTST YATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLAMHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVD TPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYTVYIDKTR

[0298] SEQ ID NO:2 Exemplary VZV GlyE cassette amino acid sequence (sometimes referred to as "insert-protein"): MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHA ESSWVNRGESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQM SAQEDLGDDTGIHVIPTLNGDDRHKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENH PFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAIQHICLKHTTCFQDVVVDVDCAENT KEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVLRTEKQYLGVYI WNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHL AQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVV YFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAA WTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEE EFGNAIGGSHGGSSYTVYIDKTR

[0299] SEQ ID NO:3 - Wild-type nucleotide sequence encoding VZV GlyE (Genbank accession number AY253715.1; which is the nucleotide sequence encoding the amino acid sequence of accession number AAP32865.1 - SEQ ID NO:1 (AAP32865.1 glycoprotein E [human alphaherpesvirus 3]):

[0300] SEQ ID NO:4 - Exemplary nucleotide sequence encoding a VZV GlyE antigen cassette / expression cassette (sometimes referred to as ">insert-vaccine")

[0301] Array number 5 ChAdOx2: A viral vector based on chimpanzee adenovirus C68 ccatcttcaa taatatacct caaacttttt gtgcgcgtta atatgcaaat gaggcgtttg 60 aatttgggga ggaagggcgg tgattggtcg agggatgagc gaccgttagg ggcggggcga 120 gtgacgtttt gatgacgtgg ttgcgaggag gagccagttt gcaagttctc gtgggaaaag 180 tgacgtcaaa cgaggtgtgg tttgaacacg gaaatactca attttcccgc gctctctgac 240 aggaaatgag gtgtttctgg gcggatgcaa gtgaaaacgg gccattttcg cgcgaaaact 300 gaatgaggaa gtgaaaatct gagtaatttc gcgtttatgg cagggaggag tatttgccga 360 gggccgagta gactttgacc gattacgtgg gggtttcgat taccgtgttt ttcacctaaa 420 tttccgcgta cggtgtcaaa gtccggtgtt tttacgcgat cgctagcgac atcgatcaca 480 agtttgtaca aaaaagctga acgagaaacg taaaatgata taaatatcaa tatattaaat 540 tagattttgc ataaaaaaca gactacataa tactgtaaaa cacaacatat ccagtcacta 600 tggcggccgc cgatttattc aacaaagcca cgttgtgtct caaaatctct gatgttacat 660 tgcacaagat aaaaatatat catcatgaac aataaaactg tctgcttaca taaacagtaa 720 tacaaggggt gttatgagcc atattcaacg ggaaacgtct tgctcgaggc cgcgattaaa 780 ttccaacatg gatgctgatt tatatgggta taaatgggct cgtgataatg tcgggcaatc 840 aggtgcgaca atctatcgat tgtatgggaa gcccgatgcg ccagagttgt ttctgaaaca 900 tggcaaaggt agcgttgcca atgatgttac agatgagatg gtcagactaa actggctgac 960 ggaatttatg cctcttccga ccatcaagca ttttatccgt actcctgatg atgcatggtt 1020 actcaccact gcgatccccg ggaaaacagc attccaggta ttagaagaat atcctgattc 1080 aggtgaaaat attgttgatg cgctggcagt gttcctgcgc cggttgcatt cgattcctgt 1140 ttgtaattgt ccttttaaca gcgatcgcgt atttcgtctc gctcaggcgc aatcacgaat 1200 gaataacggt ttggttgatg cgagtgattt tgatgacgag cgtaatggct ggcctgttga 1260 acaagtctgg aaagaaatgc ataagctttt gccattctca ccggattcag tcgtcactca 1320 tggtgatttc tcacttgata accttatttt tgacgagggg aaattaatag gttgtattga 1380 tgttggacga gtcggaatcg cagaccgata ccaggatctt gccatcctat ggaactgcct 1440 cggtgagttt tctccttcat tacagaaacg gctttttcaa aaatatggta ttgataatcc 1500 tgatatgaat aaattgcagt ttcatttgat gctcgatgag tttttctaat cagaattggt 1560 taattggttg taacactggc acgcgtggat ccggcttact aaaagccaga taacagtatg 1620 cgtatttgcg cgctgatttt tgcggtataa gaatatatac tgatatgtat acccgaagta 1680 tgtcaaaaag aggtatgcta tgaagcagcg tattacagtg acagttgaca gcgacagcta 1740 tcagttgctc aaggcatata tgatgtcaat atctccggtc tggtaagcac aaccatgcag 1800 aatgaagccc gtcgtctgcg tgccgaacgc tggaaagcgg aaaatcagga agggatggct 1860 gaggtcgccc ggtttattga aatgaacggc tcttttgctg acgagaacag gggctggtga 1920 aatgcagttt aaggtttaca cctataaaag agagagccgt tatcgtctgt ttgtggatgt 1980 acagagtgat attattgaca cgcccgggcg acggatggtg atccccctgg ccagtgcacg 2040 tctgctgtca gataaagtct cccgtgaact ttacccggtg gtgcatatcg gggatgaaag 2100 ctggcgcatg atgaccaccg atatggccag tgtgccggtc tccgttatcg gggaagaagt 2160 ggctgatctc agccaccgcg aaaatgacat caaaaacgcc attaacctga tgttctgggg 2220 aatataaatg tcaggctccc ttatacacag ccagtctgca ggtcgaccat agtgactgga 2280 tatgttgtgt tttacagtat tatgtagtct gttttttatg caaaatctaa tttaatatat 2340 tgatatttat atcattttac gtttctcgtt cagctttctt gtacaaagtg gtgatcgatt 2400 cgacagatcg cgatcgcaag tgagtagtgt tctggggcgg gggaggacct gcatgagggc 2460 cagaataact gaaatctgtg cttttctgtg tgttgcagca gcatgagcgg aagcggctcc 2520 tttgagggag gggtattcag cccttatctg acggggcgtc tcccctcctg ggcgggagtg 2580 cgtcagaatg tgatgggatc cacggtggac ggccggcccg tgcagcccgc gaactcttca 2640 accctgacct atgcaaccct gagctcttcg tcgttggacg cagctgccgc cgcagctgct 2700 gcatctgccg ccagcgccgt gcgcggaatg gccatgggcg ccggctacta cggcactctg 2760 gtggccaact cgagttccac caataatccc gccagcctga acgaggagaa gctgttgctg 2820 ctgatggccc agctcgaggc cttgacccag cgcctgggcg agctgaccca gcaggtggct 2880 cagctgcagg agcagacgcg ggccgcggtt gccacggtga aatccaaata aaaaatgaat 2940 caataaataa acggagacgg ttgttgattt taacacagag tctgaatctt tatttgattt 3000 ttcgcgcgcg gtaggccctg gaccaccggt ctcgatcatt gagcacccgg tggatctttt 3060 ccaggacccg gtagaggtgg gcttggatgt tgaggtacat gggcatgagc ccgtcccggg 3120 ggtggaggta gctccattgc agggcctcgt gctcgggggt ggtgttgtaa atcacccagt 3180 catagcaggg gcgcagggca tggtgttgca caatatcttt gaggaggaga ctgatggcca 3240 cgggcagccc tttggtgtag gtgtttacaa atctgttgag ctgggaggga tgcatgcggg 3300 gggagatgag gtgcatcttg gcctggatct tgagattggc gatgttaccg cccagatccc 3360 gcctggggtt catgttgtgc aggaccacca gcacggtgta tccggtgcac ttggggaatt 3420 tatcatgcaa cttggaaggg aaggcgtgaa agaatttggc gacgcctttg tgcccgccca 3480 ggttttccat gcactcatcc atgatgatgg cgatgggccc gtgggcggcg gcctgggcaa 3540 agacgtttcg ggggtcggac acatcatagt tgtggtcctg ggtgaggtca tcataggcca 3600 ttttaatgaa tttggggcgg agggtgccgg actgggggac aaaggtaccc tcgatcccgg gggcgtagtt cccctcacag atctgcatct cccaggcttt gagctcggag ggggggatca 3720. tgtccacctg cggggcgata aagaacacgg tttccggggc gggggagatg agctgggccg 3780 aaagcaagtt ccggagcagc tgggacttgc cgcagccggt ggggccgtag atgaccccga 3840 tgaccggctg caggtggtag ttgaggggaga gacagctgcc gtcctcccgg aggagggggg 3900 ccacctcgtt catcatctcg cgcacgtgca tgttctcgcg caccagttcc gccaggaggc 3960 gctctccccc cagggatagg agctcctgga gcgaggcga gtttttcagc ggcttgagtc cgtcggccat gggcattttg gagagggttt gttgcaagag ttccaggcgg tcccagagct 4080. cggtgatgtg ctctacggca tctcgatcca gcagacctcc tcgtttcggcg ggttggggacg 4140. gctgcgggag tagggcacca gcgatgggc gtccagcgca gccagggtcc ggtccttcca 4200. gggtcgcagc gtccgcgtca gggtggtctc cgtcacggtg aaggggtgcg cgccgggctg 4260 ggcgcttgcg agggtgcgct tcaggctcat ccggctggtc gaaaaccgct cccgatcggc 4320 gccctgcgcg tcggccaggt agcaattgac catgagttcg tagttgagcg cctcggccgc 4380 gtggcctttg gcgcggagct tacctttgga agtctgcccg caggcgggac agaggaggga 4440 cttgagggcg tagagcttgg gggcgaggaa gacggactcg ggggcgtagg cgtccgcgcc 4500 gcagtgggcg cagacggtct cgcactccac gagccaggtg aggtcgggct ggtcggggtc 4560 aaaaaccagt ttcccgccgt tctttttgat gcgtttctta cctttggtct ccatgagctc 4620 gtgtccccgc tgggtgacaa agaggctgtc cgtgtccccg tagaccgact ttatgggccg 4680 gtcctcgagc ggtgtgccgc ggtcctcctc gtagaggaac cccgcccact ccgagacgaa 4740 agcccgggtc caggccagca cgaaggaggc cacgtgggac gggtagcggt cgttgtccac 4800 cagcgggtcc accttttcca gggtatgcaa acacatgtcc ccctcgtcca catccaggaa 4860 ggtgattggc ttgtaagtgt aggccacgtg accgggggtc ccggccgggg gggtataaaa 4920 gggtgcgggt ccctgctcgt cctcactgtc ttccggatcg ctgtccagga gcgccagctg 4980 ttggggtagg tattccctct cgaaggcggg catgacctcg gcactcaggt tgtcagtttc 5040 tagaaacgag gaggatttga tattgacggt gccggcggag atgcctttca agagcccctc 5100 gtccatctgg tcagaaaaga cgatcttttt gttgtcgagc ttggtggcga aggagccgta 5160 gagggcgttg gagaggagct tggcgatgga gcgcatggtc tggttttttt ccttgtcggc 5220 gcgctccttg gcggcgatgt tgagctgcac gtactcgcgc gccacgcact tccattcggg 5280 gaagacggtg gtcagctcgt cgggcacgat tctgacctgc cagccccgat tatgcagggt 5340 gatgaggtcc acactggtgg ccacctcgcc gcgcaggggc tcattagtcc agcagaggcg 5400 tccgcccttg cgcgagcaga aggggggcag ggggtccagc atgacctcgt cgggggggtc 5460 ggcatcgatg gtgaagatgc cgggcaggag gtcggggtca aagtagctga tggaagtggc 5520 cagatcgtcc agggcagctt gccattcgcg cacggccagc gcgcgctcgt agggactgag 5580 gggcgtgccc cagggcatgg gatgggtaag cgcggaggcg tacatgccgc agatgtcgta 5640 gacgtagagg ggctcctcga ggatgccgat gtaggtgggg tagcagcgcc ccccgcggat 5700 gctggcgcgc acgtagtcat acagctcgtg cgagggggcg aggagccccg ggcccaggtt 5760 ggtgcgactg ggcttttcgg cgcggtagac gatctggcgg aaaatggcat gcgagttgga 5820 ggagatggtg ggcctttgga agatgttgaa gtgggcgtgg ggcagtccga ccgagtcgcg 5880 gatgaagtgg gcgtaggagt cttgcagctt ggcgacgagc tcggcggtga ctaggacgtc 5940 cagagcgcag tagtcgaggg tctcctggat gatgtcatac ttgagctgtc ccttttgttt 6000 ccacagctcg cggttgagaa ggaactcttc gcggtccttc cagtactctt cgagggggaa 6060 cccgtcctga tctgcacggt aagagcctag catgtagaac tggttgacgg ccttgtaggc 6120 gcagcagccc ttctccacgg ggagggcgta ggcctgggcg gccttgcgca gggaggtgtg 6180 cgtgagggcg aaagtgtccc tgaccatgac cttgaggaac tggtgcttga agtcgatatc 6240 gtcgcagccc ccctgctccc agagctggaa gtccgtgcgc ttcttgtagg cggggttggg 6300 caaagcgaaa gtaacatcgt tgaagaggat cttgcccgcg cggggcataa agttgcgagt 6360 gatgcggaaa ggttggggca cctcggcccg gttgttgatg acctgggcgg cgagcacgat 6420 ctcgtcgaag ccgttgatgt tgtggcccac gatgtagagt tccacgaatc gcggacggcc 6480 cttgacgtgg ggcagtttct tgagctcctc gtaggtgagc tcgtcggggt cgctgagccc 6540 gtgctgctcg agcgcccagt cggcgagatg ggggttggcg cggaggaagg aagtccagag 6600 atccacggcc agggcggttt gcagacggtc ccggtactga cggaactgct gcccgacggc 6660 cattttttcg ggggtgacgc agtagaaggt gcgggggtcc ccgtgccagc gatcccattt 6720 gagctggagg gcgagatcga gggcgagctc gacgagccgg tcgtccccgg agagtttcat 6780 gaccagcatg aaggggacga gctgcttgcc gaaggacccc atccaggtgt aggtttccac 6840 atcgtaggtg aggaagagcc tttcggtgcg aggatgcgag ccgatgggga agaactggat 6900 ctcctgccac caattggagg aatggctgtt gatgtgatgg aagtagaaat gccgacggcg 6960 cgccgaacac tcgtgcttgt gtttatacaa gcggccacag tgctcgcaac gctgcacggg 7020 atgcacgtgc tgcacgagct gtacctgagt tcctttgacg aggaatttca gtgggaagtg 7080 gagtcgtggc gcctgcatct cgtgctgtac tacgtcgtgg tggtcggcct ggccctcttc 7140 tgcctcgatg gtggtcatgc tgacgagccc gcgcgggagg caggtccaga cctcggcgcg 7200 agcgggtcgg agagcgagga cgagggcgcg caggccggag ctgtccaggg tcctgagacg 7260 ctgcggagtc aggtcagtgg gcagcggcgg cgcgcggttg acttgcagga gtttttccag 7320 ggcgcgcggg aggtccagat ggtacttgat ctccaccgcg ccattggtgg cgacgtcgat 7380 ggcttgcagg gtcccgtgcc cctggggtgt gaccaccgtc ccccgtttct tcttgggcgg 7440 ctggggcgac gggggcggtg cctcttccat ggttagaagc ggcggcgagg acgcgcgccg 7500 ggcggcaggg gcggctcggg gcccggaggc aggggcggca ggggcacgtc ggcgccgcgc 7560 gcgggtaggt tctggtactg cgcccggaga agactggcgt gagcgacgac gcgacggttg 7620 acgtcctgga tctgacgcct ctgggtgaag gccacgggac ccgtgagttt gaacctgaaa 7680 gagagttcga cagaatcaat ctcggtatcg ttgacggcgg cctgccgcag gatctcttgc 7740 acgtcgcccg agttgtcctg gtaggcgatc tcggtcatga actgctcgat ctcctcctct 7800 tgaaggtctc cgcggccggc gcgctccacg gtggccgcga ggtcgttgga gatgcggccc 7860 atgagctgcg agaaggcgtt catgcccgcc tcgttccaga cgcggctgta gaccacgacg 7920 ccctcgggat cgccggcgcg catgaccacc tgggcgaggt tgagctccac gtggcgcgtg 7980 aagaccgcgt agttgcagag gcgctggtag aggtagttga gcgtggtggc gatgtgctcg 8040 gtgacgaaga aatacatgat ccagcggcgg agcggcatct cgctgacgtc gcccagcgcc 8100 tccaaacgtt ccatggcctc gtaaaagtcc acggcgaagt tgaaaaactg ggagttgcgc 8160 gccgagacgg tcaactcctc ctccagaaga cggatgagct cggcgatggt ggcgcgcacc 8220 tcgcgctcga aggccccgg gagttcctcc acttctctctt cttctctctc cactaacatc 8280 tcttctactt cctctccagg cggcagtggt ggcgggggag ggggcctgcg tcgccggcgg 8340 cgcacgggca gacggtcgat gaagcgctcg atggtctcgc cgcgccggcg tcgcatggtc 8400 tcggtgacgg cgcgcccgtc ctcgcggggc cgcagcgtga agacgccgcc gcgcatctcc 8460 aggtggccgg gggggtcccc gttgggcagg gagagggcgc tgacgatgca tcttatcaat 8520 tgccccgtag ggactccgcg caaggacctg agcgtctcga gatccacggg atctgaaaac 8580 cgctgaacga aggcttcgag ccagtcgcag tcgcaaggta ggctgagcac ggtttcttct ggcgggtcat gttggttggg agcggggcgg gcgatgctgc tggtgatgaa gttgaaatag 8700. gcggttctga gacggcggat ggtggcgagg agcaccaggt ctttgggccc ggcttgctgg 8760 atgcgcagac ggtcggccat gccccaggcg tggtcctgac acctggccag gtccttgtag 8820 tagtcctgca tgagccgctc cacgggcacc tcctcctcgc ccgcgcggcc gtgcatgcgc 8880 gtgagcccga agccgcgctg gggctggacg agcgccaggt cggcgacgac gcgctcggcg 8940 aggatggctt gctggatctg ggtgagggtg gtctggagt catcaaagtc gacgaagcgg tggtaggctc cggtgttgat ggtgtaggag cagttggcca tgacggacca gttgacggtc 9060 tggtggcccg gacgcacgag ctcgtggtac ttgaggcgcg agtagcgcg cgtgtcgag 9120 atgtagtcgt tgcaggtgcg caccaggtac tggtagccga tgaggaagtg cggcggcggc tggcggtaga gcggccatcg ctcggtggcg ggggcgccgg gcgcgaggtc ctcgagcatg 9240 gtgcggtggt agccgtagat gtacctggac atccaggtga tgccggcggc ggtggtggag 9300 gcgcgcggga actcgcggac gcggttccag atgttgcgca gcggcaggaa gtagttcatg 9360 gtgggcacgg tctggcccgt gaggcgcgcg cagtcgtgga tgctctatac gggcaaaaac 9420 gaaagcggtc agcggctcga ctccgtggcc tggaggctaa gcgaacgggt tgggctgcgc 9480 gtgtaccccg gttcgaatct cgaatcaggc tggagccgca gctaacgtgg tattggcact 9540 cccgtctcga cccaagcctg caccaaccct ccaggatacg gaggcgggtc gttttgcaac 9600 ttttttttgg aggccggatg agactagtaa gcgcggaaag cggccgaccg cgatggctcg 9660 ctgccgtagt ctggagaaga atcgccaggg ttgcgttgcg gtgtgccccg gttcgaggcc 9720 ggccggattc cgcggctaac gagggcgtgg ctgccccgtc gtttccaaga ccccatagcc 9780 agccgacttc tccagttacg gagcgagccc ctcttttgtt ttgtttgttt ttgccagatg 9840 catcccgtac tgcggcagat gcgcccccac caccctccac cgcaacaaca gccccctcca 9900 cagccggcgc ttctgccccc gccccagcag caacttccag ccacgaccgc cgcggccgcc 9960 gtgagcgggg ctggacagag ttatgatcac cagctggcct tggaagaggg cgaggggctg 10020 gcgcgcctgg gggcgtcgtc gccggagcgg cacccgcgcg tgcagatgaa aagggacgct 10080 cgcgaggcct acgtgcccaa gcagaacctg ttcagagaca ggagcggcga ggagcccgag 10140 gagatgcgcg cggcccggtt ccacgcgggg cgggagctgc ggcgcggcct ggaccgaaag 10200 agggtgctga gggacgagga tttcgaggcg gacgagctga cggggatcag ccccgcgcgc 10260 gcgcacgtgg ccgcggccaa cctggtcacg gcgtacgagc agaccgtgaa ggaggagagc 10320 aacttccaaa aatccttcaa caaccacgtg cgcaccctga tcgcgcgcga ggaggtgacc 10380 ctgggcctga tgcacctgtg ggacctgctg gaggccatcg tgcagaaccc caccagcaag 10440 ccgctgacgg cgcagctgtt cctggtggtg cagcatagtc gggacaacga agcgttcagg 10500 gaggcgctgc tgaatatcac cgagcccgag ggccgctggc tcctggacct ggtgaacatt 10560 ctgcagagca tcgtggtgca ggagcgcggg ctgccgctgt ccgagaagct ggcggccatc 10620 aacttctcgg tgctgagttt gggcaagtac tacgctagga agatctacaa gaccccgtac 10680 gtgcccatag acaaggaggt gaagatcgac gggttttaca tgcgcatgac cctgaaagtg 10740 ctgaccctga gcgacgatct gggggtgtac cgcaacgaca ggatgcaccg tgcggtgagc 10800 gccagcaggc ggcgcgagct gagcgaccag gagctgatgc atagtctgca gcgggccctg 10860 accggggccg ggaccgaggg ggagagctac tttgacatgg gcgcggacct gcactggcag 10920 cccagccgcc gggccttgga ggcggggggca ggaccctacg tagagaaggt ggacgatgag 10980 gtggacgagg agggcgagta cctggaagac tgatggcgcg accgtatttt tgctagatgc 11040 aacaacaaca gccacctcct gatcccgcga tgcgggcggc gctccagagc cagccgtccg 11100 gcattaactc ctcggacgat tggacccagg ccatgcaacg catcatggcg ctgacgaccc 11160 gcaacccga agcctttaga cagcagcccc aggccaaccg gctctcggcc atcctggagg 11220 ccgtggtgcc ctcgcgctcc aaccccacgc acgagaaggt cctggccatc gtgaacgcgc 11280 tggtggagaa caaggccatc cgcggcgacg aggccggcct ggtgtacaac gcgctgctgg 11340 agcgcgtggc ccgctacaac agcaccaacg tgcagaccaa cctggaccgc atggtgaccg 11400 acgtgcgcga ggccgtggcc cagcgcgagc ggttccaccg cgagtccaac ctgggatcca 11460 tggtggcgct gaacgccttc ctcagcaccc agcccgccaa cgtgccccgg ggccaggagg 11520 actacaccaa cttcatcagc gccctgcgcc tgatggtgac cgaggtgccc cagagcgagg 11580 tgtaccagtc cgggccggac tacttcttcc agaccagtcg ccagggcttg cagaccgtga 11640 acctgagcca ggctttcaag aacttgcagg gcctgtgggg cgtgcaggcc ccggtcgggg 11700 accgcgcgac ggtgtcgagc ctgctgacgc cgaactcgcg cctgctgctg ctgctggtgg 11760 cccccttcac ggacagcggc agcatcaacc gcaactcgta cctgggctac ctgattaacc 11820 tgtaccgcga ggccatcggc caggcgcacg tggacgagca gacctaccag gagatcaccc 11880 acgtgagccg cgccctgggc caggacgacc cgggcaacct ggaagccacc ctgaactttt 11940 tgctgaccaa ccggtcgcag aagatcccgc cccagtacgc gctcagcacc gaggaggagc 12000 gcatcctgcg ttacgtgcag cagagcgtgg gcctgttcct gatgcaggag ggggccaccc 12060 ccagcgccgc gctcgacatg accgcgcgca acatggagcc cagcatgtac gccagcaacc 12120 gcccgttcat caataaactg atggactact tgcatcgggc ggccgccatg aactctgact 12180 atttcaccaa cgccatcctg aatccccact ggctcccgcc gccggggttc tacacgggcg 12240 agtacgacat gcccgacccc aatgacgggt tcctgtggga cgatgtggac agcagcgtgt 12300 tctccccccg accgggtgct aacgagcgcc ccttgtggaa gaaggaaggc agcgaccgac 12360 gcccgtcctc ggcgctgtcc ggccgcgagg gtgctgccgc ggcggtgccc gaggccgcca 12420 gtcctttccc gagcttgccc ttctcgctga acagtatccg cagcagcgag ctgggcagga 12480 tcacgcgccc gcgcttgctg ggcgaagagg agtacttgaa tgactcgctg ttgagacccg 12540 agcgggagaa gaacttcccc aataacggga tagaaagcct ggtggacaag atgagccgct 12600 ggaagacgta tgcgcaggag cacagggacg atccccgggc gtcgcagggg gccacgagcc 12660 ggggcagcgc cgcccgtaaa cgccggtggc acgacaggca gcggggacag atgtgggacg 12720 atgaggactc cgccgacgac agcagcgtgt tggacttggg tgggagtggt aacccgttcg 12780 ctcacctgcg cccccgtatc gggcgcatga tgtaagagaa accgaaaata aatgatactc 12840 accaaggcca tggcgaccag cgtgcgttcg tttcttctct gttgttgttg tatctagtat 12900 gatgaggcgt gcgtacccgg agggtcctcc tccctcgtac gagagcgtga tgcagcaggc 12960 gatggcggcg gcggcgatgc agcccccgct ggaggctcct tacgtgcccc cgcggtacct 13020 ggcgcctacg gaggggcgga acagcattcg ttactcggag ctggcaccct tgtacgatac 13080 cacccggttg tacctggtgg acaacaagtc ggcggacatc gcctcgctga actaccagaa 13140 cgaccacagc aacttcctga ccaccgtggt gcagaacaat gacttcaccc ccacggaggc 13200 cagcacccag accatcaact ttgacgagcg ctcgcggtgg ggcggccagc tgaaaaccat 13260 catgcacacc aacatgccca acgtgaacga gttcatgtac agcaacaagt tcaaggcgcg 13320 ggtgatggtc tcccgcaaga cccccaatgg ggtgacagtg acagaggatt atgatggtag 13380 tcaggatgag ctgaagtatg aatgggtgga atttgagctg cccgaaggca acttctcggt 13440 gaccatgacc atcgacctga tgaacaacgc catcatcgac aattacttgg cggtggggcg 13500 gcagaacggg gtgctggaga gcgacatcgg cgtgaagttc gacactagga acttcaggct 13560 gggctgggac cccgtgaccg agctggtcat gcccggggtg tacaccaacg aggctttcca 13620 tcccgatatt gtcttgctgc ccggctgcgg ggtggacttc accgagagcc gcctcagcaa 13680 cctgctgggc attcgcaaga ggcagccctt ccaggaaggc ttccagatca tgtacgagga 13740 tctggagggg ggcaacatcc ccgcgctcct ggatgtcgac gcctatgaga aaagcaagga 13800 ggatgcagca gctgaagcaa ctgcagccgt agctaccgcc tctaccgagg tcaggggcga 13860 taattttgca agcgccgcag cagtggcagc ggccgaggcg gctgaaaccg aaagtaagat 13920 agtcattcag ccggtggaga aggatagcaa gaacaggagc tacaacgtac taccggacaa 13980 gataaacacc gcctaccgca gctggtacct agcctacaac tatggcgacc ccgagaaggg 14040 cgtgcgctcc tggacgctgc tcaccacctc ggacgtcacc tgcggcgtgg agcaagtcta 14100 ctggtcgctg cccgacatga tgcaagaccc ggtcaccttc cgctccacgc gtcaagttag 14160 caactacccg gtggtgggcg ccgagctcct gcccgtctac tccaagagct tcttcaacga 14220 gcaggccgtc tactcgcagc agctgcgcgc cttcacctcg cttacgcacg tcttcaaccg 14280 cttccccgag aaccagatcc tcgtccgccc gcccgcgccc accattacca ccgtcagtga 14340 aaacgttcct gctctcacag atcacgggac cctgccgctg cgcagcagta tccggggagt 14400 ccagcgcgtg accgttactg acgccagacg ccgcacctgc ccctacgtct acaaggccct 14460 gggcatagtc gcgccgcgcg tcctctcgag ccgcaccttc taaatgtcca ttctcatctc 14520 gcccagtaat aacaccggtt ggggcctgcg cgcgcccagc aagatgtacg gaggcgctcg 14580 ccaacgctcc acgcaacacc ccgtgcgcgt gcgcgggcac ttccgcgctc cctggggcgc 14640 cctcaagggc cgcgtgcggt cgcgcaccac cgtcgacgac gtgatcgacc aggtggtggc 14700 cgacgcgcgc aactacaccc ccgccgccgc gcccgtctcc accgtggacg ccgtcatcga 14760 cagcgtggtg gcggacgcgc gccggtacgc ccgcgccaag agccggcggc ggcgcatcgc 14820 ccggcggcac cggagcaccc ccgccatgcg cgcggcgcga gccttgctgc gcagggccag 14880 gcgcacggga cgcagggcca tgctcagggc ggccagacgc gcggcttcag gcgccagcgc 14940 cggcaggacc cggagacgcg cggccacggc ggcggcagcg gccatcgcca gcatgtcccg 15000 cccgcggcga gggaacgtgt actgggtgcg cgacgccgcc accggtgtgc gcgtgcccgt 15060 gcgcacccgc ccccctcgca cttgaagatg ttcacttcgc gatgttgatg tgtcccagcg 15120 gcgaggagga tgtccaagcg caaattcaag gaagagatgc tccaggtcat cgcgcctgag 15180 atctacggcc ctgcggtggt gaaggaggaa agaaagcccc gcaaaatcaa gcgggtcaaa 15240 aaggacaaaa aggaagaaga aagtgatgtg gacggattgg tggagtttgt gcgcgagttc 15300 gccccccggc ggcgcgtgca gtggcgcggg cggaaggtgc aaccggtgct gagacccggc 15360 accaccgtgg tcttcacgcc cggcgagcgc tccggcaccg cttccaagcg ctcctacgac 15420 gaggtgtacg gggatgatga tattctggag caggcggccg agcgcctggg cgagtttgct 15480 tacggcaagc gcagccgttc cgcaccgaag gaagaggcgg tgtccatccc gctggaccac 15540 ggcaacccca cgccgagcct caagcccgtg accttgcagc aggtgctgcc gaccgcggcg 15600 ccgcgccggg ggttcaagcg cgagggcgag gatctgtacc ccaccatgca gctgatggtg 15660 cccaagcgcc agaagctgga agacgtgctg gagaccatga aggtggaccc ggacgtgcag 15720 cccgaggtca aggtgcggcc catcaagcag gtggccccgg gcctgggcgt gcagaccgtg 15780 gacatcaaga ttcccacgga gcccatggaa acgcagaccg agcccatgat caagcccagc 15840 accagcacca tggaggtgca gacggatccc tggatgccat cggctcctag tcgaagaccc 15900 cggcgcaagt acggcgcggc cagcctgctg atgcccaact acgcgctgca tccttccatc 15960 atccccacgc cgggctaccg cggcacgcgc ttctaccgcg gtcataccag cagccgccgc 16020 cgcaagacca ccactcgccg ccgccgtcgc cgcaccgccg ctgcaaccac ccctgccgcc 16080 ctggtgcgga gagtgtaccg ccgcggccgc gcacctctga ccctgccgcg cgcgcgctac 16140 cacccgagca tcgccattta aactttcgcc agctttgcag atcaatggcc ctcacatgcc 16200 gccttcgcgt tcccattacg ggctaccgag gaaaaacc gcgccgtaga aggctggcgg 16260 ggaacgggat gcgtcgccac caccaccggc ggcggcgcgc catcagcaag cggttggggg 16320 gaggcttcct gcccgcgctg atccccatca tcgccgcggc gatcggggcg atccccggca 16380 ttgcttccgt ggcggtgcag gcctctcagc gccactgaga cacacttgga aacatcttgt 16440 aataaaccca tggactctga cgctcctggt cctgtgatgt gttttcgtag acagatggaa 16500 gacatcaatt tttcgtccct ggctccgcga cacggcacgc ggccgttcat gggcacctgg 16560 agcgacatcg gcaccagcca actgaacggg ggcgccttca attggagcag tctctggagc 16620 gggcttaaga atttcgggtc cacgcttaaa acctatggca gcaaggcgtg gaacagcacc 16680 acagggcagg cgctgaggga taagctgaaa gagcagaact tccagcagaa ggtggtcgat 16740 gggctcgcct cgggcatcaa cggggtggtg gacctggcca accaggccgt gcagcggcag 16800 atcaacagcc gcctggaccc ggtgccgccc gccggctccg tggagatgcc gcaggtggag 16860 gaggagctgc ctcccctgga caagcggggc gagaagcgac cccgccccga tgcggaggag 16920 acgctgctga cgcacacgga cgagccgccc ccgtacgagg aggcggtgaa actgggtctg 16980 cccaccacgc ggcccatcgc gcccctggcc accggggtgc tgaaacccga aaagcccgcg 17040 accctggact tgcctcctcc ccagccttcc cgcccctcta cagtggctaa gcccctgccg 17100 ccggtggccg tggcccgcgc gcgacccggg ggcaccgccc gccctcatgc gaactggcag 17160 agcactctga acagcatcgt gggtctggga gtgcagagtg tgaagcgccg ccgctgctat 17220 taaacctacc gtagcgctta acttgcttgt ctgtgtgtgt atgtattatg tcgccgccgc 17280 cgctgtccac cagaaggagg agtgaagagg cgcgtcgccg agttgcaaga tggccacccc 17340 atcgatgctg ccccagtggg cgtacatgca catcgccgga caggacgctt cggagtacct 17400 gagtccgggt ctggtgcagt ttgcccgcgc cacagacacc tacttcagtc tggggaacaa 17460 gtttaggaac cccacggtgg cgcccacgca cgatgtgacc accgaccgca gccagcggct 17520 gacgctgcgc ttcgtgcccg tggaccgcga ggacaacacc tactcgtaca aagtgcgcta 17580 cacgctggcc gtgggcgaca accgcgtgct ggacatggcc agcacctact ttgacatccg 17640 cggcgtgctg gatcggggcc ctagcttcaa accctactcc ggcaccgcct acaacagtct 17700 ggcccccaag ggagcaccca acacttgtca gtggacatat aaagccgatg gtgaaactgc 17760. cacagaaaa acctatacat atggaaatgc acccgtgcag ggcattaaca tcacaaaaga tggtattcaa cttggaactg acaccgatga tcagccaatc tacgcagata aaacctatca gcctgaacct caagtgggtg atgctgaatg gcatgacatc actggtactg atgaaaagta tggaggcaga gctcttaagc ctgataccaa aatgaagcct tgttatggtt cttttgccaa gcctactaat aaagaaggag gtcaggcaaa tgtgaaaaca ggaacaggca ctactaaaga atatgacata gacatggctt tctttgacaa cagaagtgcg gctgctgctg gcctagctcc agaaattgtt ttgtatactg aaaatgtgga tttggaaact ccagataccc atattgtata 18240. 18240. 18240. 18240. 18240. 18240. 18240. 18240. 18240. 18240 18300. 18300. 18300. 18300. 18300. 18300. 18300. 18300. 18300 tggcaatatg ggggtgctgg ccggtcaggc ttctcagctg aatgctgtgg ttgacttgca 18360 agacagaaac accgagctgt cctaccagct cttgcttgac tctctgggtg acagaacccg 18420 gtatttcagt atgtggaatc aggcggtgga cagctatgat cctgatgtgc gcattattga 18480 aaatcatggt gtggaggatg aacttcccaa ctattgtttc cctctggatg ctgttggcag 18540 aacagatact tatcagggaa ttaaggctaa tggaactgat caaaccacat ggaccaaaga 18600 tgacagtgtc aatgatgcta atgagatagg caagggtaat ccattcgcca tggaaatcaa 18660 catccaagcc aacctgtgga ggaacttcct ctacgccaac gtggccctgt acctgcccga 18720 ctcttacaag tacacgccgg ccaatgttac cctgcccacc aacaccaaca cctacgatta 18780 catgaacggc cgggtggtgg cgccctcgct ggtggactcc tacatcaaca tcggggcgcg 18840 ctggtcgctg gatcccatgg acaacgtgaa ccccttcaac caccaccgca atgcggggct 18900 gcgctaccgc tccatgctcc tgggcaacgg gcgctacgtg cccttccaca tccaggtgcc 18960 ccagaaattt ttcgccatca agagcctcct gctcctgccc gggtcctaca cctacgagtg 19020 gaacttccgc aaggacgtca acatgatcct gcagagctcc ctcggcaacg acctgcgcac 19080 ggacggggcc tccatctcct tcaccagcat caacctctac gccaccttct tccccatggc 19140 gcacaacacg gcctccacgc tcgaggccat gctgcgcaac gacaccaacg accagtcctt 19200 caacgactac ctctcggcgg ccaacatgct ctaccccatc ccggccaacg ccaccaacgt 19260 gcccatctcc atcccctcgc gcaactgggc cgccttccgc ggctggtcct tcacgcgtct 19320 caagaccaag gagacgccct cgctgggctc cgggttcgac ccctacttcg tctactcggg 19380 ctccatcccc tacctcgacg gcaccttcta cctcaaccac accttcaaga aggtctccat 19440 caccttcgac tcctccgtca gctggcccgg caacgaccgg ctcctgacgc ccaacgagtt 19500 cgaaatcaag cgcaccgtcg acggcgaggg ctacaacgtg gcccagtgca acatgaccaa 19560 ggactggttc ctggtccaga tgctggccca ctacaacatc ggctaccagg gcttctacgt 19620 gcccgagggc tacaaggacc gcatgtactc cttcttccgc aacttccagc ccatgagccg 19680 ccaggtggtg gacgaggtca actacaagga ctaccaggcc gtcaccctgg cctaccagca 19740 caacaactcg ggcttcgtcg gctacctcgc gcccaccatg cgccagggcc agccctaccc 19800 cgccaactac ccctacccgc tcatcggcaa gagcgccgtc accagcgtca cccagaaaaa 19860 gttcctctgc gacagggtca tgtggcgcat ccccttctcc agcaacttca tgtccatggg 19920 cgcgctcacc gacctcggcc agaacatgct ctatgccaac tccgcccacg cgctagacat 19980 gaatttcgaa gtcgacccca tggatgagtc cacccttctc tatgttgtct tcgaagtctt 20040 cgacgtcgtc cgagtgcacc agccccaccg cggcgtcatc gaggccgtct acctgcgcac 20100 ccccttctcg gccggtaacg ccaccaccta agctcttgct tcttgcaagc catggccgcg 20160 ggctccggcg agcaggagct cagggccatc atccgcgacc tgggctgcgg gccctacttc 20220 ctgggcacct tcgataagcg cttcccggga ttcatggccc cgcacaagct ggcctgcgcc 20280 atcgtcaaca cggccggccg cgagaccggg ggcgagcact ggctggcctt cgcctggaac 20340 ccgcgctcga acacctgcta cctcttcgac cccttcgggt tctcggacga gcgcctcaag 20400 cagatctacc agttcgagta cgagggcctg ctgcgccgca gcgccctggc caccgaggac 20460 cgctgcgtca ccctggaaaa gtccacccag accgtgcagg gtccgcgctc ggccgcctgc 20520 gggctcttct gctgcatgtt cctgcacgcc ttcgtgcact ggcccgaccg ccccatggac 20580 aagaacccca ccatgaactt gctgacgggg gtgcccaacg gcatgctcca gtcgccccag 20640 gtggaaccca ccctgcgccg caaccaggag gcgctctacc gcttcctcaa ctcccactcc 20700 gcctactttc gctcccaccg cgcgcgcatc gagaaggcca ccgccttcga ccgcatgaat 20760 caagacatgt aaaccgtgtg tgtatgttaa atgtctttaa taaacagcac tttcatgtta 20820 cacatgcatc tgagatgatt tatttagaaa tcgaaagggt tctgccgggt ctcggcatgg 20880 cccgcgggca gggacacgtt gcggaactgg tacttggcca gccacttgaa ctcggggatc 20940 agcagtttgg gcagcggggt gtcggggaag gagtcggtcc acagcttccg cgtcagttgc 21000 agggcgccca gcaggtcggg cgcggagatc ttgaaatcgc agttgggacc cgcgttctgc 21060 gcgcgggagt tgcggtacac ggggttgcag cactggaaca ccatcagggc cgggtgcttc 21120 acgctcgcca gcaccgtcgc gtcggtgatg ctctccacgt cgaggtcctc ggcgttggcc 21180 atcccgaagg gggtcatctt gcaggtctgc cttcccatgg tgggcacgca cccgggcttg 21240 tggttgcaat cgcagtgcag ggggatcagc atcatctggg cctggtcggc gttcatcccc 21300 gggtacatgg ccttcatgaa agcctccaat tgcctgaacg cctgctgggc cttggctccc 21360 tcggtgaaga agaccccgca ggacttgcta gagaactggt tggtggcgca cccggcgtcg 21420 tgcacgcagc agcgcgcgtc gttgttggcc agctgcacca cgctgcgccc ccagcggttc 21480 tgggtgatct tggcccggtc ggggttctcc ttcagcgcgc gctgcccgtt ctcgctcgcc 21540 acatccatct cgatcatgtg ctccttctgg atcatggtgg tcccgtgcag gcaccgcagc 21600 ttgccctcgg cctcggtgca cccgtgcagc cacagcgcgc acccggtgca ctcccagttc 21660 ttgtgggcga tctgggaatg cgcgtgcacg aagccctgca ggaagcggcc catcatggtg 21720 gtcagggtct tgttgctagt gaaggtcagc ggaatgccgc ggtgctcctc gttgatgtac 21780 aggtggcaga tgcggcggta cacctcgccc tgctcgggca tcagctggaa gttggctttc 21840 aggtcggtct ccacgcggta gcggtccatc agcatagtca tgatttccat acccttctcc 21900 caggccgaga cgatgggcag gctcataggg ttcttcacca tcatcttagc gctagcagcc 21960 gcggccaggg ggtcgctctc gtccagggtc tcaaagctcc gcttgccgtc cttctcggtg 22020 atccgcaccg gggggtagct gaagcccacg gccgccagct cctcctcggc ctgtctttcg 22080 tcctcgctgt cctggctgac gtcctgcagg accacatgct tggtcttgcg gggtttcttc 22140 ttgggcggca gcggcggcgg agatgttgga gatggcgagg gggagcgcga gttctcgctc 22200 accactacta tctcttcctc ttcttggtcc gaggccacgc ggcggtaggt atgtctcttc 22260 gggggcagag gcggaggcga cgggctctcg ccgccgcgac ttggcggatg gctggcagag 22320 ccccttccgc gttcgggggt gcgctcccgg cggcgctctg actgacttcc tccgcggccg 22380 gccattgtgt tctcctaggg aggaacaaca agcatggaga ctcagccatc gccaacctcg 22440 ccatctgccc ccaccgccga cgagaagcag cagcagcaga atgaagctt aaccgccccg 22500 ccgcccagcc ccgccaccctc cgacgcggcc gtcccagaca tgcaagagat ggaggaatcc 22560 atcgagattg acctgggcta tgtgacgccc gcggagcacg aggaggact ggcagtgcgc 22620 ttttcacaag aagagataca ccagaacag ccagagcagg aagcagagaa tgagcagagt 22680 caggctgggc tcgagcatga cggcgactac ctccacctga gcggggggga ggacgcgctc 22740 atcaagcatc tggcccggca ggccaccatc gtcaggatg cgctgctcga ccgcaccgag 22800 gtgcccctca gcgtggagga gctcagccgc gcctacgagt tgaacctt ctcgccgcgc 22860 gtgcccccca agcgccagcc caatggcacc tgcgagcccca acccgcgcct caacctac 22920 ccggtcttcg cggtgcccga ggccctggcc acctaccaca tcttttcaa gaaccaaag 22980 atccccgtct cctgccgcgc caccgcacc cgcgccgacg cccttca cctgggtccc 23040 ggcgcccgcc tacctgatat cgcctccttg gagaggttc ccagatct cgagggtctg 23100 ggcagcgacg agactcgggc cgcgaacgct ctgcaaggag aaggaggaga gcatgagcac 23160 cacagcgccc tggtcgagtt ggaaggcgac aacgcgcggc tggcggtgct caaacgcacg 23220 gtcgagctga cccatttcgc ctacccggct ctgaacctgc cccccaaagt catgagcgcg 23280 gtcatggacc aggtgctcat caagcgcgcg tcgcccatct ccgaggacga gggcatgcaa 23340 gactccgagg agggcaagcc cgtggtcagc gacgagcagc tggcccggtg gctgggtcct 23400 aatgctagtc cccagagttt ggaagagcgg cgcaaactca tgatggccgt ggtcctggtg 23460 accgtggagc tggagtgcct gcgccgcttc ttcgccgacg cggagaccct gcgcaaggtc 23520 gaggagaacc tgcactacct cttcaggcac gggttcgtgc gccaggcctg caagatctcc 23580 aacgtggagc tgaccaacct ggtctcctac atgggcatct tgcacgagaa ccgcctgggg 23640 cagaacgtgc tgcacaccac cctgcgcggg gaggcccggc gcgactacat ccgcgactgc 23700 gtctacctct acctctgcca cacctggcag acgggcatgg gcgtgtggca gcagtgtctg 23760 gaggagcaga acctgaaaga gctctgcaag ctcctgcaga agaacctcaa gggtctgtgg 23820 accgggttcg acgagcgcac caccgcctcg gacctggccg acctcatttt ccccgagcgc 23880 ctcaggctga cgctgcgcaa cggcctgccc gactttatga gccaaagcat gttgcaaaac 23940 tttcgctctt tcatcctcga acgctccgga atcctgcccg ccacctgctc cgcgctgccc 24000 tcggacttcg tgccgctgac cttccgcgag tgccccccgc cgctgtggag ccactgctac 24060 ctgctgcgcc tggccaacta cctggcctac cactcggacg tgatcgagga cgtcagcggc 24120 gagggcctgc tcgagtgcca ctgccgctgc aacctctgca cgccgcaccg ctccctggcc 24180 tgcaaccccc agctgctgag cgagacccag atcatcggca ccttcgagtt gcaagggccc 24240 agcgaaggcg agggttcagc cgccaagggg ggtctgaaac tcaccccggg gctgtggacc 24300 tcggcctact tgcgcaagtt cgtgcccgag gactaccatc ccttcgagat caggttctac 24360 gaggaccaat cccatccgcc caaggccgag ctgtcggcct gcgtcatcac ccagggggcg 24420 atcctggccc aattgcaagc catccagaaa tcccgccaag aattcttgct gaaaaagggc 24480 cgcggggtct acctcgaccc ccagaccggt gaggagctca accccggctt cccccaggat 24540 gccccgagga aacaagaagc tgaaagtgga gctgccgccc gtggaggatt tggaggaaga 24600 ctgggagaac agcagtcagg cagaggagga ggagatggag gaagactggg acagcactca 24660 ggcagaggag gacagcctgc aagacagtct ggaggaagac gaggaggagg cagaggagga 24720 ggtggaagaa gcagccgccg ccagaccgtc gtcctcggcg ggggagaaag caagcagcac 24780 ggataccatc tccgctccgg gtcggggtcc cgctcgacca cacagtagat gggacgagac 24840 cggacgattc ccgaacccca ccacccagac cggtaagaag gagcggcagg gatacaagtc 24900 ctggcggggg cacaaaaacg ccatcgtctc ctgcttgcag gcctgcgggg gcaacatctc 24960 cttcacccgg cgctacctgc tcttccaccg cggggtgaac tttccccgca acatcttgca 25020 ttactaccgt cacctccaca gcccctacta cttccaagaa gaggcagcag cagcagaaaa 25080 agaccagcag aaaaccagca gctagaaaat ccacagcggc ggcagcaggt ggactgagga 25140 tcgcggcgaa cgagccggcg caaacccggg agctgaggaa ccggatcttt cccaccctct 25200 atgccatctt ccagcagagt cgggggcagg agcaggaact gaaagtcaag aaccgttctc tgcgctcgct cacccgcagt tgtctgtatc acaagagcga agaccaactt cagcgcactc tcgaggacgc cgaggctctc ttcaacaagt actgcgcgct cactcttaaa gagtagcccg cgcccgccca gtcgcagaaa aaggcggga ttacgtcacc tgtgcccttc gccctagccg cctccaccca tcatcatgag caaagagatt cccacgcctt acatgtggag ctaccagccc 25560. cagatgggcc tggccgccgg tgccgcccag gactactcca cccgcatgaa ttggctcagc gccggggcccg cgatgatctc acgggtgaat gacatccgcg cccaccgaaa ccagatactc ctagaacagt cagcgctcac cgccacgccc cgcaatcacc tcaatccgcg taattggccc gccgccctgg tgtaccagga aattccccag cccacgaccg tactacttcc gcgagacgcc 25740 caggccgag tccagctgac taactcaggt gtccagctgg cgggcggcgc caccctgtgt 25800 25860. cgtcaccgcc ccgctcaggg fathercgg ctggtgatcc ggggcagagg cacacagctc aacgacgagg tggtgagctc ttcgctgggt ctgcgacctg acggagtctt ccaactcgcc 25920 ggatcgggga gatcttcctt cacgcctcgt caggccgtcc tgactttgga gagttcgtcc 25980 tcgcagcccc gctcgggtgg catcggcact ctccagttcg tggaggagtt cactccctcg 26040 gtctacttca accccttctc cggctccccc ggccactacc cggacgagtt catcccgaac 26100 ttcgacgcca tcagcgagtc ggtggacggc tacgattgag tttaaactca cccccttatc 26160 cagtgaaata aagatcatat tgatgatgat tttacagaaa taaaaaataa tcatttgatt 26220 tgaaataaag atacaatcat attgatgatt tgagtttaac aaaaaaataa agaatcactt 26280 acttgaaatc tgataccagg tctctgtcca tgttttctgc caacaccact tcactcccct 26340 cttcccagct ctggtactgc aggccccggc gggctgcaaa cttcctccac acgctgaagg 26400 ggatgtcaaa ttcctcctgt ccctcaatct tcattttatc ttctatcaga tgtccaaaaa 26460 gcgcgtccgg gtggatgatg acttcgaccc cgtctacccc tacgatgcag acaacgcacc 26520 gaccgtgccc ttcatcaacc cccccttcgt ctcttcagat ggattccaag agaagcccct 26580 ggggggtgttg tccctgcgac tggccgaccc cgtcaccacc aagaacgggg aaatcaccct 26640 caagctggga gaggggttgg acctcgattc ctcgggaaaa ctcatctcca acacggccac caaggccgcc gcccctctca gtttttcca cacaccatt tcccttaaca tggatcaccc cttttacact aaagatgga aattatcctt acaagtttct crack atatactgag 26880. aacaagcatt ctaaacacac tagctttagg ttttggatca ggtttaggac tccgtggctc tgccttggca gtacagttag tctctccact tacatttgat actgatggaa acataaagct 27000. 27000. 27000. 27000. 27000. 27000. 27000. 27000. 27000. 27000 ggctaaaggt ttaaaatttg aagatggagc catagcaacc aacattgga atgggttaga gtttggaagc hold aaacaggtgt tgatgatgct tacccaatcc aagttaaact tggatctggc cttagctttg acagtacagg agccataatg gctggtaaca aagaagacga taaactcact ttgtggacaa cacctgatcc atcaccaaac tgtcaataac tcgcagaaaa tgatgcaaaa ctaacacttt gcttgactaa atgtggtagt caaatactgg ccactgtgtc agtcttagtt gtaggaagtg gaaacctaaa ccccattact ggcaccgtaa gcagtgctca 27360 ggtgtttcta cgttttgatg caaacggtgt tcttttaaca gaacattcta cactaaaaaa 27420 atactggggg tataggcagg gagatagcat agatggcact cCATacca atgctgtagg 27480 attcatgccc aatttaaaag cttatccaaa gtcacaaagt tctactacta aaaataatat 27540 agtagggcaa gtatacatga atggagatgt ttcaaaacct atgcttctca ctataaccct 27600 caatggtact gatgacagca acagtacata ttcaatgtca ttttcataca cctggactaa 27660 tggaagctat gttggagcaa catttgggc taactcttat accttctcat acatcgccca 27720 agaatgaaca ctgtatccca ccctgcatgc caacccttcc caccccactc tgtggaacaa 27780 actctgaaac acaaaataaa ataaagttca agtgttttat tgattcaaca gtttcacaga 27840 accctagtat tcaacctgcc acctccctcc caacacacag agtacacagt cctttctccc 27900 cggctggcct taaaaagcat catatcatgg gtaacagaca tattcttagg tgttatattc 27960 cacacggttt cctgtcgagc caaacgctca tcagtgatat taataaactc cccgggcagc 28020 tcacttaagt tcatgtcgct gtccagctgc tgagccacag gctgctgtcc aacttgcggt 28080 tgcttaacgg gcggcgaagg agaagtccac gcctacatgg gggtagagtc ataatcgtgc 28140 atcaggatag ggcggtggtg ctgcagcagc gcgcgaataa actgctgccg ccgccgctcc 28200 gtcctgcagg aatacaacat ggcagtggtc tcctcagcga tgattcgcac cgcccgcagc 28260 ataaggcgcc ttgtcctccg ggcacagcag cgcaccctga tctcacttaa atcagcacag 28320 taactgcagc acagcaccac aatattgttc aaaatcccac agtgcaaggc gctgtatcca 28380 aagctcatgg cggggaccac agaacccacg tggccatcat accacaagcg caggtagatt 28440 aagtggcgac ccctcataaa cacgctggac ataaacatta cctcttttgg catgttgtaa 28500 ttcaccacct cccggtacca tataaacctc tgattaaaca tggcgccatc caccaccatc 28560 ctaaaccagc tggccaaaac ctgcccgccg gctatacact gcagggaacc gggactggaa 28620 caatgacagt ggagagccca ggactcgtaa ccatggatca tcatgctcgt catgatatca 28680 atgttggcac aacacaggca cacgtgcata cacttctcca ggattacaag ctctccccgc 28740 gttagaacca tatcccaggg aacaacccat tcctgaatca gcgtaaatcc caacactgcag 28800 ggaagacctc gcacgtaact cacgttgtgc attgtcaaag tgttacattc gggcagcagc 28860 ggatgatcct ccagtatggt agcgcgggtt tctgtctcaa aaagggtag acgatcccta 28920 ctgtacggag tgcgccgaga caaccgagat cgtgttggtc gtagtgtcat gccaaatgga 28980 acgccggacg tagtcatatt tcctgaagca aaaccaggtg cgggcgtgac aaacagatct 29040 gcgtctccgg tctcgccgct tagatcgctc tgtgtagtag ttgtagtata tccactctct 29100 caaagcatcc aggcgccccc tggcttcggg ttctatgtaa actctcttcat gcgccgctgc 29160 cctgataaca tccaccaccg cagaataagc caacccagc caacctacac attcgttctg 29220 cgagtcacac acgggaggag cgggaagagc tggagaacc atgattaact ttattccaaa 29280 cggtctcgga gcacttcaaa atgcaggtcc cggaggtggc acctctcgcc cccactgtgt 29340 tggtggaaaa taacagccag gtcaaggtg acacggttct cgagatgttc cacggtggct 29400 tccagcaag cctccacgcg cacatccaga aaaagagga cagcgaaagc gggagcgttt 29460 tctaattcct caatcatcat attackac tgcaccatcc ccagatatt ttcattttc 29520 cagccttgaa tgattcgtat tagttcctga ggtaaatcca agccagccat gataaaaagc 29580 tcgcgcagag cgccctccac cggcattctt aagcacaccc tcatattcc aagagattct 29640 gctcctggtt cacctgcagc agattaacaa tgggaatatc aaaatctctg ccgcgatccc 29700 taagctccctc cctcacaat aactgtagt aatctttcat atcatctccg aaatttttag 29760 ccataggggcc gccaggaata agagcaggggc agccacatt acagataag cgaagtccctc 29820 cccagtgwgc attgccaaat gtaagattga ataagcatg ctggctagac cctgtgatat 29880 cttccagata actggacaga aaatcaggca agcaatttt aagaaaatca aaaagaaa 29940 agtcgtccag gtgcaggtttt agagcctcag gaacaacgat ggaatagtg caggagtgc 30000 gttccagcat ggttagtgtt ttttggtga tctgtagaac aaaaaataaa catgcaat 30060 taaaccatgc tagcctggcg aacaggtggg taaatcactc ttccagcac tagcaggct 30120 acggggtctc cggcgcgacc ctcgtagaag ctgtcgccat gattgaaag catcaccgag 30180 agaccttccc gtggccggc atggatt cgagagaag catacactcc gggacattg 30240 gcatccgtga gtgaaaaaaaa gcgacctata aagcctcggg gcactacaat gctcaatctc 30300 aattccagca aagccacccc atgcggatgg agcacaaat tggcaggtgc gtaaaaaatg 30360 taattactcc cctcctgcac aggcagcaaa gcccccgctc cctccagaaa cacatacaa 30420 gcctcagcgt ccatagctta ccgagcacgg caggcgcaag agtcagagaa aaggctgagc 30480 tctaacctga ctgcccgctc ctgtgctcaa tatatagcccc taacctac tgacgtaag 30540 gccaaagtct aaaaataccc gccaaataat cacacacgcc cagcacacgc cacaaaccg 30600 gtgacacact caaaaaata cgcgcactc ctcaacgcc caaactgcc gtcattccg 30660 gttcccacg ctacgtcatc aaaaacacgac ttcaattc cgtcgaccgt taaaaacgtc 30720 acccgccccg cccctaacgg tcgcccgtct ctcagccaat cagcgccccg catccccaaa 30780 ttcaaacacc tcatttgcat attaacgcgc acaaaaagtt tgaggtatat tattgatgat 30840 gg 30842

[0302] SEQ ID NO:6-bgh polyadenylation signal ctgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatc gcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatgg

[0303] SEQ ID NO: 7: Long CMV promoter

Claims

1. 1. A vaccine composition comprising a viral vector comprising a nucleic acid having a polynucleotide sequence encoding at least one epitope of a Varicella-Zoster Virus (VZV) GlyE antigen, wherein the viral vector is an adenoviral vector ChAdO x1.

2. 2. The vaccine composition of claim 1, wherein the at least one epitope comprises at least one CD4 T cell epitope and at least one CD8 T cell epitope.

3. The vaccine composition according to claim 1 or 2, which does not contain an adjuvant.

4. The vaccine composition according to any one of claims 1 to 3, wherein the GlyE antigen has the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:

2.

5. 5. The vaccine composition of claim 4, wherein the GlyE antigen has the amino acid sequence of SEQ ID NO:

2.

6. A vaccine composition according to any one of claims 1 to 5, wherein the polynucleotide sequence comprises the sequence of SEQ ID NO:3 or SEQ ID NO:

4.

7. The vaccine composition of claim 6, wherein the polynucleotide sequence comprises the sequence of SEQ ID NO:

4.

8. The vaccine composition according to any one of claims 1 to 7, wherein the polynucleotide sequence further comprises the sequence of SEQ ID NO: 6 of the bgh polyadenylation signal.

9. The vaccine composition according to any one of claims 1 to 8, wherein a polynucleotide sequence encoding at least one epitope of the Varicella-Zoster Virus (VZV) GlyE antigen is operably linked to a long CMV promoter.

10. 10. The vaccine composition of claim 9, wherein the long CMV promoter has the nucleotide sequence of SEQ ID NO:

7.

11. The viral vector sequence was deposited under ECACC Accession No. 12052403. x1 The vaccine composition according to any one of claims 1 to 10, wherein the nucleotide sequence is (E4 modification).

12. The vaccine composition of any of claims 1 to 11, wherein administration of a single dose to a mammalian subject induces protective immunity in said subject.

13. The vaccine composition according to any one of claims 1 to 12, for inducing an immune response against VZV.

14. The vaccine composition according to any one of claims 1 to 13 for inducing an immune response against VZV, which is administered in a single dose.

15. A vaccine composition according to any one of claims 1 to 14 for inducing an immune response against VZV, which is administered once.

16. A vaccine composition according to any one of claims 1 to 14 for inducing an immune response against VZV, which is administered once every 5 years or once a year.

17. The vaccine composition according to any one of claims 1 to 16, for preventing VZV infection.

18. A vaccine composition according to any one of claims 1 to 17 for the prevention of shingles.

19. A vaccine composition according to any of claims 1 to 18 for preventing VZV infection or for preventing shingles, wherein a single dose is administered.

20. A vaccine composition according to any one of claims 1 to 19 for preventing VZV infection or for preventing shingles, which is administered once.

21. Use of a vaccine composition according to any of claims 1 to 20 in the preparation of a medicament for the prevention of VZV infection.

22. Use of a vaccine composition according to any one of claims 1 to 20 in the preparation of a medicament for the prevention of shingles.

23. Use of a vaccine composition according to any of claims 1 to 20 for inducing, or in the preparation of a medicament for inducing, both a CD4+ and a CD8+ T cell response against a GlyE antigen in a subject.

24. 24. The use of claim 23, wherein the medicament further induces antibodies against the GlyE antigen in the subject.

25. A vaccine composition according to any one of claims 1 to 17 for the treatment or prevention of chickenpox.

Citation Information

Patent Citations

  • Recombinant varicella-zoster virus

    EP1721981A1

  • DNA vaccine composition for preventing and treating herpes zoster, and method for activating t cells for VZV antigen by using same

    EP3210631A1

  • WC500053460

  • Varicella zoster virus-virus like particles (VLPS) and antigens

    WO2009012486A1

  • Conditionally replication deficient herpes viruses and use thereof in vaccines

    WO2014043189A1